[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5047
1. Rastogi A, Sharma P: Short-Segment Barrett's Esophagus and Adenocarcinoma. Gastroenterol Hepatol (N Y); 2006 Feb;2(2):134-139

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-Segment Barrett's Esophagus and Adenocarcinoma.
  • Barrett's esophagus is a known risk factor for the development of adenocarcinoma of the esophagus and esophagogastric junction.
  • The rapid rise in the incidence of esophageal adenocarcinoma has generated sustained research interest in this lesion.
  • Studies have shown that although the prevalence of short-segment Barrett's esophagus is higher than that of long-segment Barrett's esophagus, the risk of developing dysplasia and adenocarcinoma may actually be lower in those patients with short segment Barrett's esophagus.
  • Nonetheless, both dysplasia and esophageal adenocarcinoma have been reported in patients with short-segment Barrett's esophagus, making this arbitrary distinction clinically unimportant.
  • Another key issue is differentiating short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1992 Jun;33(6):733-7 [1624150.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Gastroenterology. 1984 Oct;87(4):927-33 [6468881.001]
  • [Cites] Am J Gastroenterol. 1999 Dec;94(12):3413-9 [10606296.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Gut. 2003 Jan;52(1):24-7 [12477754.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1541-6 [7557137.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):414-8 [9068460.001]
  • [Cites] Dig Dis Sci. 2002 Sep;47(9):2108-11 [12353864.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):277-85 [9922307.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1249-56 [2703113.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):559-65 [11323579.001]
  • [Cites] Gastrointest Endosc. 1987 Dec;33(6):413-6 [3443258.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):913-8 [10201456.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1378-82 [11374671.001]
  • [Cites] Gut. 1997 Nov;41(5):585-9 [9414961.001]
  • [Cites] Endoscopy. 1993 Nov;25(9):652-4 [8119225.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1930-6 [12190156.001]
  • [Cites] Ann Intern Med. 2000 Apr 18;132(8):612-20 [10766679.001]
  • [Cites] Dig Dis Sci. 1997 Mar;42(3):597-602 [9073145.001]
  • [Cites] N Engl J Med. 1986 Aug 7;315(6):362-71 [2874485.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):14-20 [14767729.001]
  • [Cites] Ann Surg. 1983 Oct;198(4):554-65 [6625723.001]
  • [Cites] Gut. 1997 Jun;40(6):710-5 [9245922.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):87-94 [11145256.001]
  • [Cites] Lancet. 1994 Dec 3;344(8936):1533-6 [7983953.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Gut. 1996 Jul;39(1):5-8 [8881798.001]
  • [Cites] Am J Gastroenterol. 1996 Aug;91(8):1507-11 [8759651.001]
  • [Cites] Gut. 2000 Jan;46(1):9-13 [10601047.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Gastrointest Endosc. 1994 Jan-Feb;40(1):111 [8163114.001]
  • [Cites] Gut. 1998 Jul;43(1):17-21 [9771400.001]
  • [Cites] Gut. 1991 Dec;32(12):1441-6 [1773946.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):289-93 [11522967.001]
  • [Cites] Dig Dis Sci. 1997 Mar;42(3):603-7 [9073146.001]
  • [Cites] Dig Dis Sci. 1992 Jan;37(1):137-43 [1728519.001]
  • [Cites] Br J Surg. 1988 Aug;75(8):760-3 [3167523.001]
  • [Cites] Am J Gastroenterol. 1994 May;89(5):670-80 [8172136.001]
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):226-31 [15729230.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1155-8 [8339208.001]
  • [Cites] Am J Gastroenterol. 1996 May;91(5):981-6 [8633592.001]
  • [Cites] Am J Gastroenterol. 1997 Nov;92(11):2012-6 [9362182.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):407-13 [9068459.001]
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] Gut. 1998 May;42(5):659-62 [9659160.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1033-6 [9672325.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1820-8 [8859198.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):294-301 [11522968.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):937-43 [10201460.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):857-9 [4033716.001]
  • (PMID = 28286441.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Barrett’s esophagus / adenocarcinoma / high-grade dysplasia / long-segment Barrett’s esophagus / low-grade dysplasia / short-segment Barrett’s esophagus
  •  go-up   go-down


2. Filomeni G, Aquilano K, Rotilio G, Ciriolo MR: Glutathione-related systems and modulation of extracellular signal-regulated kinases are involved in the resistance of AGS adenocarcinoma gastric cells to diallyl disulfide-induced apoptosis. Cancer Res; 2005 Dec 15;65(24):11735-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione-related systems and modulation of extracellular signal-regulated kinases are involved in the resistance of AGS adenocarcinoma gastric cells to diallyl disulfide-induced apoptosis.
  • In the present work, we report that DADS is ineffective in inducing apoptosis in a human adenocarcinoma gastric cell line (AGS).
  • In particular, we show that AGS cells are able to recover from the p53/p21-mediated cell cycle arrest in the G(2)-M phase upon DADS treatment without committing cells to death.
  • [MeSH-major] Allyl Compounds / pharmacology. Apoptosis / drug effects. Disulfides / pharmacology. Drug Resistance, Neoplasm. Glutathione / metabolism. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Cell Division / drug effects. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. G2 Phase / drug effects. Glutathione Peroxidase / metabolism. Humans. Reactive Oxygen Species / metabolism. Sulfhydryl Compounds / metabolism. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIALLYL DISULFIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357186.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Allyl Compounds; 0 / Antineoplastic Agents; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Disulfides; 0 / Reactive Oxygen Species; 0 / Sulfhydryl Compounds; 0 / Tumor Suppressor Protein p53; 2179-57-9 / diallyl disulfide; EC 1.11.1.9 / Glutathione Peroxidase; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; GAN16C9B8O / Glutathione
  •  go-up   go-down


3. Cover TL, Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology; 2009 May;136(6):1863-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori is highly adapted for colonization of the human stomach and is present in about half of the human population.
  • When present, H pylori is usually the numerically dominant gastric microorganism.
  • H pylori typically does not cause any adverse effects, but it is associated with an increased risk of noncardia gastric adenocarcinoma, gastric lymphoma, and peptic ulcer.
  • In this review, we discuss biologic factors that allow H pylori to colonize the human stomach, mechanisms by which H pylori increases the risk of peptic ulcer disease and noncardia gastric adenocarcinoma, and potential benefits that H pylori might confer to humans.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS One. 2008;3(7):e2836 [18665274.001]
  • [Cites] Gut. 2008 Oct;57(10):1375-85 [18467372.001]
  • [Cites] Infect Immun. 2008 Dec;76(12):5632-44 [18794279.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):329-38 [19138977.001]
  • [Cites] Cell Microbiol. 2009 Mar;11(3):488-505 [19046339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12778-83 [10535999.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14547-52 [10588742.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14559-64 [10588744.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1497-500 [10688800.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] Nat Med. 2000 May;6(5):536-42 [10802709.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7533-8 [10852959.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2206-11 [11007219.001]
  • [Cites] J Infect Dis. 2000 Nov;182(5):1446-9 [11015236.001]
  • [Cites] EMBO J. 2000 Dec 1;19(23):6361-70 [11101509.001]
  • [Cites] J Exp Med. 2000 Dec 4;192(11):1601-10 [11104802.001]
  • [Cites] Clin Microbiol Rev. 2001 Jan;14(1):59-97 [11148003.001]
  • [Cites] Epidemiol Rev. 2000;22(2):283-97 [11218379.001]
  • [Cites] Infect Immun. 2001 Feb;69(2):730-6 [11159961.001]
  • [Cites] J Clin Invest. 2001 Mar;107(5):611-20 [11238562.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1319-22 [11283049.001]
  • [Cites] J Clin Invest. 2001 Apr;107(7):767-73 [11285290.001]
  • [Cites] Gut. 2001 Sep;49(3):324-9 [11511551.001]
  • [Cites] FEMS Microbiol Lett. 2001 Sep 11;203(1):109-14 [11557148.001]
  • [Cites] J Bacteriol. 2001 Nov;183(22):6499-508 [11673417.001]
  • [Cites] Pediatrics. 2001 Nov;108(5):E87 [11694671.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13844-9 [11717441.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14607-12 [11717398.001]
  • [Cites] Science. 2002 Jan 25;295(5555):683-6 [11743164.001]
  • [Cites] Gut. 2002 Mar;50(3):295-8 [11839704.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6775-8 [11788577.001]
  • [Cites] J Immunol. 2002 Mar 15;168(6):2603-7 [11884423.001]
  • [Cites] Mol Microbiol. 2001 Dec;42(5):1337-48 [11886563.001]
  • [Cites] Microbiology. 2002 May;148(Pt 5):1447-56 [11988519.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8354-9 [12060779.001]
  • [Cites] Cell Microbiol. 2002 May;4(5):285-96 [12064285.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):414-24 [12145793.001]
  • [Cites] N Engl J Med. 2002 Oct 10;347(15):1175-86 [12374879.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):58-66 [9649459.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10212-7 [9707626.001]
  • [Cites] Infect Immun. 1998 Oct;66(10):4856-66 [9746590.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12619-24 [9770535.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2001-6 [10051584.001]
  • [Cites] Gastroenterology. 1999 Apr;116(4):823-30 [10092304.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):671-2 [10227288.001]
  • [Cites] J Infect Dis. 1999 Jun;179(6):1523-30 [10228075.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):520-4 [10404065.001]
  • [Cites] EMBO J. 1999 Oct 15;18(20):5517-27 [10523296.001]
  • [Cites] Int J Syst Evol Microbiol. 2004 Nov;54(Pt 6):2203-11 [15545459.001]
  • [Cites] Am J Gastroenterol. 2004 Nov;99(11):2121-7 [15554990.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):10-6 [15483107.001]
  • [Cites] J Infect Dis. 2005 Feb 15;191(4):579-87 [15655782.001]
  • [Cites] Cell Microbiol. 2005 Feb;7(2):191-8 [15659063.001]
  • [Cites] Nat Rev Microbiol. 2005 Apr;3(4):320-32 [15759043.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7952-7 [15911771.001]
  • [Cites] Science. 2005 Jun 10;308(5728):1635-8 [15831718.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9247-52 [15956202.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9661-6 [15980153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10646-51 [16027366.001]
  • [Cites] Am J Epidemiol. 2005 Sep 15;162(6):579-84 [16093294.001]
  • [Cites] J Struct Biol. 2005 Sep;151(3):215-28 [16125415.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16339-44 [16258069.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):732-7 [16407106.001]
  • [Cites] World J Gastroenterol. 2005 Dec 14;11(46):7277-83 [16437628.001]
  • [Cites] PLoS Genet. 2005 Oct;1(4):e43 [16217547.001]
  • [Cites] Ann Epidemiol. 2006 May;16(5):347-51 [16246582.001]
  • [Cites] J Bacteriol. 2006 May;188(10):3449-62 [16672598.001]
  • [Cites] Science. 2006 Jun 2;312(5778):1355-9 [16741115.001]
  • [Cites] Mol Microbiol. 2006 Aug;61(4):847-60 [16879643.001]
  • [Cites] Nat Med. 2006 Sep;12(9):1030-8 [16951684.001]
  • [Cites] EMBO Rep. 2006 Oct;7(10):956-60 [17016449.001]
  • [Cites] Clin Microbiol Rev. 2006 Oct;19(4):597-613 [17041136.001]
  • [Cites] Nat Rev Microbiol. 2006 Nov;4(11):826-36 [17041630.001]
  • [Cites] N Engl J Med. 2006 Nov 23;355(21):2226-35 [17124020.001]
  • [Cites] Infect Immun. 2007 Jan;75(1):334-41 [17074854.001]
  • [Cites] Infect Immun. 2007 Feb;75(2):1005-16 [17101654.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2927-32 [17293459.001]
  • [Cites] Arch Intern Med. 2007 Apr 23;167(8):821-7 [17452546.001]
  • [Cites] Gastroenterology. 2007 May;132(5):1820-33 [17484877.001]
  • [Cites] Nat Rev Microbiol. 2007 Jun;5(6):441-52 [17505524.001]
  • [Cites] Nature. 2007 May 17;447(7142):326-9 [17507983.001]
  • [Cites] Nature. 2007 May 17;447(7142):330-3 [17507984.001]
  • [Cites] J Natl Cancer Inst. 2007 Sep 5;99(17):1328-34 [17728213.001]
  • [Cites] PLoS Comput Biol. 2007 Aug;3(8):e151 [17696605.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):926-36 [17854597.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5433-40 [17911630.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16293-8 [17911250.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):843-9 [17943121.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):862-6 [17943123.001]
  • [Cites] Cell Host Microbe. 2007 Oct 11;2(4):250-63 [18005743.001]
  • [Cites] Annu Rev Pathol. 2006;1:63-96 [18039108.001]
  • [Cites] Gut. 2008 Jan;57(1):16-24 [17761783.001]
  • [Cites] Evolution. 2008 Jan;62(1):39-49 [17976191.001]
  • [Cites] Cell Host Microbe. 2008 Jan 17;3(1):20-9 [18191791.001]
  • [Cites] J Med Microbiol. 2008 Feb;57(Pt 2):145-50 [18201978.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):1003-8 [18192401.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):491-9 [18242215.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):1049-57 [18395086.001]
  • [Cites] Gut. 2008 May;57(5):561-7 [18194986.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2350-7 [18397989.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):91-9 [18474244.001]
  • [Cites] J Infect Dis. 2008 Aug 15;198(4):553-60 [18598192.001]
  • [Cites] J Infect Dis. 1986 Apr;153(4):658-63 [3950447.001]
  • [Cites] J Clin Pathol. 1987 Aug;40(8):841-8 [3654985.001]
  • [Cites] Emerg Infect Dis. 2006 Nov;12(11):1701-8 [17283620.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):915-8 [17287725.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14428-33 [12391297.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):745-55 [12419219.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15136-41 [12411577.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 20;94(22):1680-7 [12441323.001]
  • [Cites] J Clin Microbiol. 2002 Dec;40(12):4504-11 [12454143.001]
  • [Cites] Cell Microbiol. 2003 Jan;5(1):25-40 [12542468.001]
  • [Cites] EMBO J. 2003 Feb 3;22(3):515-28 [12554652.001]
  • [Cites] Microbiology. 2003 Jan;149(Pt 1):121-9 [12576586.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):951-7 [12615708.001]
  • [Cites] Science. 2003 Mar 7;299(5612):1582-5 [12624269.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12101-8 [12562777.001]
  • [Cites] J Exp Med. 2003 Apr 7;197(7):813-22 [12668646.001]
  • [Cites] Gut. 2003 May;52(5):637-40 [12692045.001]
  • [Cites] J Infect Dis. 2003 Apr 15;187(8):1165-77 [12695995.001]
  • [Cites] Infect Immun. 2003 Jun;71(6):3529-39 [12761138.001]
  • [Cites] Science. 2003 May 30;300(5624):1430-4 [12775840.001]
  • [Cites] Dig Dis Sci. 2003 Jun;48(6):1068-72 [12822864.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):26734-41 [12738773.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):364-71 [12891537.001]
  • [Cites] Science. 2003 Aug 22;301(5636):1099-102 [12934009.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):48204-9 [13129933.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1887-97 [14676300.001]
  • [Cites] J Clin Invest. 2004 Feb;113(3):321-33 [14755326.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1852-7 [14769936.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] FASEB J. 2004 Mar;18(3):439-56 [15003990.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4250-5 [15016918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 18;101(20):7727-32 [15128946.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):586-93 [15210820.001]
  • [Cites] Am J Med. 2004 Sep 15;117(6):429-32 [15380500.001]
  • [Cites] Nat Immunol. 2004 Nov;5(11):1166-74 [15489856.001]
  • [Cites] Lancet. 1984 Jun 16;1(8390):1311-5 [6145023.001]
  • [Cites] Eur J Epidemiol. 2001;17(9):823-7 [12081100.001]
  • [Cites] Science. 2002 Jul 26;297(5581):573-8 [12142529.001]
  • [Cites] Ann Intern Med. 1988 Jul 1;109(1):11-7 [3288028.001]
  • [Cites] Mayo Clin Proc. 1988 Dec;63(12):1176-80 [3199885.001]
  • [Cites] Lancet. 1988 Dec 24-31;2(8626-8627):1437-42 [2904568.001]
  • [Cites] N Engl J Med. 1989 Dec 7;321(23):1562-6 [2586553.001]
  • [Cites] Nutr Cancer. 1990;13(1-2):59-65 [2300494.001]
  • [Cites] Gastroenterology. 1990 Sep;99(3):697-702 [2379775.001]
  • [Cites] Gastroenterology. 1991 Jul;101(1):167-74 [2044906.001]
  • [Cites] Infect Immun. 1992 Apr;60(4):1714-6 [1548097.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10570-5 [1587837.001]
  • [Cites] J Infect Dis. 1993 Jul;168(1):219-21 [8515114.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9720-4 [7937879.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] J Biol Chem. 1995 Jul 28;270(30):17771-7 [7629077.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1777-80 [7473834.001]
  • [Cites] Biochemistry. 1996 Feb 20;35(7):2498-504 [8652594.001]
  • [Cites] Int J Epidemiol. 1996 Jun;25(3):494-504 [8671549.001]
  • [Cites] J Infect Dis. 1996 Sep;174(3):552-6 [8769613.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14648-53 [8962108.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):92-9 [8978347.001]
  • [Cites] J Infect Dis. 1997 May;175(5):1240-2 [9129095.001]
  • [Cites] J Exp Med. 1998 Jan 5;187(1):135-40 [9419220.001]
  • [Cites] Science. 1998 Jan 16;279(5349):373-7 [9430586.001]
  • [Cites] J Clin Invest. 1998 Jul 1;102(1):51-6 [9649556.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):50-7 [9649458.001]
  • (PMID = 19457415.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM063270; United States / NIGMS NIH HHS / GM / R01GM63270; United States / NIAID NIH HHS / AI / R01 AI39657; United States / NIAID NIH HHS / AI / R01 AI039657; United States / NIAID NIH HHS / AI / R01 AI068009
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 165
  • [Other-IDs] NLM/ NIHMS462294; NLM/ PMC3644425
  •  go-up   go-down


Advertisement
4. Piccirillo S, Filomeni G, Brüne B, Rotilio G, Ciriolo MR: Redox mechanisms involved in the selective activation of Nrf2-mediated resistance versus p53-dependent apoptosis in adenocarcinoma cells. J Biol Chem; 2009 Oct 2;284(40):27721-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Redox mechanisms involved in the selective activation of Nrf2-mediated resistance versus p53-dependent apoptosis in adenocarcinoma cells.
  • We have investigated the role of reactive oxygen species and thiol-oxidizing agents in the induction of cell death and have shown that adenocarcinoma gastric (AGS) cells respond differently to the oxidative challenge according to the signaling pathways activated.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. NF-E2-Related Factor 2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2008 May;9(5):402-12 [18431400.001]
  • [Cites] J Natl Cancer Inst. 2008 Apr 16;100(8):580-95 [18398104.001]
  • [Cites] Mol Cell Biochem. 2008 Nov;318(1-2):23-31 [18587629.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jul;8(7):579-91 [19478820.001]
  • [Cites] Oncogene. 1999 Nov 1;18(45):6104-11 [10557101.001]
  • [Cites] Nat Cell Biol. 2000 Jun;2(6):339-45 [10854324.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):420-30 [10930377.001]
  • [Cites] Methods Enzymol. 2002;347:317-26 [11898422.001]
  • [Cites] Circ Res. 2002 Jun 28;90(12):1259-66 [12089063.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1423-5 [12205035.001]
  • [Cites] Mol Pharmacol. 2002 Nov;62(5):1001-10 [12391262.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7305-15 [12499274.001]
  • [Cites] FASEB J. 2003 Jan;17(1):64-6 [12424221.001]
  • [Cites] Oncogene. 2003 Mar 27;22(12):1860-5 [12660821.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1441-4 [14641084.001]
  • [Cites] Drug Resist Updat. 2004 Apr;7(2):97-110 [15158766.001]
  • [Cites] Free Radic Biol Med. 2004 Jun 15;36(12):1505-16 [15182853.001]
  • [Cites] Free Radic Biol Med. 2004 Nov 15;37(10):1578-90 [15477009.001]
  • [Cites] Environ Health Perspect. 1985 Dec;64:259-64 [3007093.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Mol Cell Biol. 1995 Jul;15(7):3892-903 [7791795.001]
  • [Cites] J Biol Chem. 1996 Oct 4;271(40):25035-40 [8798786.001]
  • [Cites] FEBS Lett. 1997 Apr 14;406(3):234-42 [9136893.001]
  • [Cites] EMBO J. 1998 May 1;17(9):2596-606 [9564042.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Trends Mol Med. 2004 Nov;10(11):549-57 [15519281.001]
  • [Cites] J Exp Med. 2005 Jan 17;201(2):279-89 [15642743.001]
  • [Cites] Biochem J. 2005 Mar 1;386(Pt 2):215-9 [15647005.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(12):4914-23 [15923610.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3853-63 [15824742.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11735-42 [16357186.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):368-80 [16673384.001]
  • [Cites] Semin Cancer Biol. 2006 Dec;16(6):420-6 [17092741.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):39776-84 [17077087.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:89-116 [16968214.001]
  • [Cites] J Biol Chem. 2007 Apr 20;282(16):12010-21 [17327230.001]
  • [Cites] EMBO J. 2007 Apr 18;26(8):2115-26 [17380123.001]
  • [Cites] Cell Death Differ. 2005 Dec;12(12):1555-63 [16151458.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Dec;8(12):1022-37 [18058573.001]
  • [Cites] J Neurochem. 2008 Mar;104(6):1599-612 [17996028.001]
  • [Cites] PLoS One. 2008;3(6):e2458 [18560558.001]
  • (PMID = 19643729.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-E2-Related Factor 2; 0 / Tumor Suppressor Protein p53; 10465-78-8 / Diamide; 52500-60-4 / Thioredoxins; BBX060AN9V / Hydrogen Peroxide; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2785700
  •  go-up   go-down


5. Aquilano K, Baldelli S, Rotilio G, Ciriolo MR: trans-Resveratrol inhibits H2O2-induced adenocarcinoma gastric cells proliferation via inactivation of MEK1/2-ERK1/2-c-Jun signalling axis. Biochem Pharmacol; 2009 Feb 1;77(3):337-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] trans-Resveratrol inhibits H2O2-induced adenocarcinoma gastric cells proliferation via inactivation of MEK1/2-ERK1/2-c-Jun signalling axis.
  • In this report we investigate the signalling pathway activated by H(2)O(2) in human adenocarcinoma gastric cells (AGS) and we evaluate the anti-proliferative action of the natural stilbene trans-resveratrol.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Proliferation / drug effects. Hydrogen Peroxide / pharmacology. MAP Kinase Signaling System / drug effects. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Stilbenes / pharmacology. Stomach Neoplasms / pathology


6. Ardeshiry Lajimi A, Rezaie-Tavirani M, Mortazavi SA, Barzegar M, Moghadamnia SH, Rezaee MB: Study of Anti Cancer Property of Scrophularia striata Extract on the Human Astrocytoma Cell Line (1321). Iran J Pharm Res; 2010;9(4):403-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of Anti Cancer Property of Scrophularia striata Extract on the Human Astrocytoma Cell Line (1321).
  • There are considerable efforts to identify naturally occurring substances as new drugs in cancer therapy.
  • This prompted us to investigate the effect of Scrophularia striata (an Iranian species belonging to the Scrophulariace family) extract on the growth of astrocyte cancer cell line (1321).
  • Striata showed strong anticancer effect on 1321cell line as compared to control group (cells not exposed to extracts), and even the group (adenocarcinoma gastric cell line) exposed to etoposide.
  • Striata contain both anti cancer and cell growth enhancing agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24381605.001).
  • [ISSN] 1735-0328
  • [Journal-full-title] Iranian journal of pharmaceutical research : IJPR
  • [ISO-abbreviation] Iran J Pharm Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3870064
  • [Keywords] NOTNLM ; 1321 cell line / Anticancer effect / Astrocytoma / Flow cytometry / Scrophularia striata extract
  •  go-up   go-down


7. Wronski M, Ziarkiewicz-Wroblewska B, Gornicka B, Cebulski W, Slodkowski M, Wasiutynski A, Krasnodebski IW: Synchronous occurrence of gastrointestinal stromal tumors and other primary gastrointestinal neoplasms. World J Gastroenterol; 2006 Sep 7;12(33):5360-2
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The synchronous stromal tumors were located in the stomach and were incidentally found during the operation.
  • The coexistent neoplasms were colon adenocarcinoma, gastric cancer (2 cases) and gastric lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Neoplasms, Second Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):682-6 [10782147.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Sep;17(9):1033-6 [12167128.001]
  • [Cites] Med Sci Monit. 2004 Aug;10(8):LE13-4 [15278004.001]
  • [Cites] World J Gastroenterol. 2006 Feb 7;12(5):815-7 [16521203.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1088-92 [6692300.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):323-4 [9697690.001]
  • [Cites] Mayo Clin Proc. 1999 Jun;74(6):543-52 [10377927.001]
  • [Cites] Pol J Pathol. 2005;56(2):51-61 [16092666.001]
  • [Cites] Cancer Res. 1970 Feb;30(2):455-65 [5458974.001]
  • (PMID = 16981268.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC4088205
  •  go-up   go-down


8. Mitruţ P, Burada F, Enescu A, Scorei R, Badea D, Genunche-Dumitrescu A, Rogoz I, Manea M: The genotoxicity study of resveratrol in primary gastric adenocarcinoma cell cultures. Rom J Morphol Embryol; 2009;50(3):429-33
Hazardous Substances Data Bank. RESVERATROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The genotoxicity study of resveratrol in primary gastric adenocarcinoma cell cultures.
  • Gastric cancer is the second most common cause of cancer-related death in the world.
  • Some studies indicate that polyphenolic compounds and antioxidants exert a protective action against gastric cancer.
  • Among the polyphenolic compounds tested and proven effective against gastric cancer is resveratrol, a natural polyphenol present in red wines and various human food items.
  • We tested the genotoxic activity of resveratrol in primary cell cultures from gastric adenocarcinoma, obtained by mucosal biopsy at upper digestive endoscopy.
  • The adenocarcinoma cells were analyzed for the presence of micronuclei at different concentrations of resveratrol at 48 hours and at 72 hours.
  • The frequency of micronuclei increased progressively with the dose of resveratrol used, the high frequency is in the primary culture initiated from gastric adenocarcinoma: signet ring cell type.
  • This results show the genotoxic activity of resveratrol in adenocarcinoma gastric cell and the anticancer property of this substance.
  • [MeSH-major] Stilbenes / pharmacology. Stilbenes / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19690770.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Stilbenes; Q369O8926L / resveratrol
  •  go-up   go-down


9. Kaira K, Sunaga N, Yanagitani N, Hisada T, Ishizuka T, Mori M: Pseudomesotheliomatous adenocarcinoma of the lung with synchronous gastric and esophageal cancer. Australas Radiol; 2007 Dec;51 Suppl:B265-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomesotheliomatous adenocarcinoma of the lung with synchronous gastric and esophageal cancer.
  • Pseudomesotheliomatous adenocarcinoma is an uncommon variant of peripheral lung cancer.
  • An immunohistochemical investigation is important when it is difficult to determine whether diffuse carcinomatous involvement of the pleura is secondary to metastasis, lung cancer, or mesothelioma.
  • We herein report a very rare case of concomitant pseudomesotheliomatous adenocarcinoma, gastric cancer and esophageal cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Diagnostic Imaging / methods. Esophageal Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Neoplasms, Second Primary / diagnosis. Stomach Neoplasms / diagnosis


10. Martínez-Luna E, Puebla-Miranda M, Vega-Memije ME: [Skin metastasis of gastric adenocarcinoma. Case report]. Rev Gastroenterol Mex; 2009 Oct-Dec;74(4):362-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin metastasis of gastric adenocarcinoma. Case report].
  • [Transliterated title] Metástasis cutáneas de adenocarcinoma gástrico; informe de un caso.
  • These lesions generally occur in late stages of disease, being uncommon their presentation at the time of diagnosis.
  • We inform the case of a male patient who presented a metastatic adenocarcinoma in the skin of the chest.
  • Under the suspect of primary tumor in the gastrointestinal tract, an upper gastrointestinal endoscopy was made corroborating diagnosis of a primary gastric cancer.
  • The case instructs the unusual morphology of cutaneous metastasis of gastric adenocarcinoma, as well appearing as the initial clinical data in an extended malignant disease.
  • Key words: cutaneous metastases, metastatic adenocarcinoma, gastric carcinoma, Mexico.
  • [MeSH-major] Adenocarcinoma / secondary. Skin Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423769.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


11. Salehi Z, Mollasalehi H, Jelodar MH, Kazemi M, Zahmatkesh R: The relationship between Helicobacter pylori infection and gastric adenocarcinoma in Northern Iran. Oncol Res; 2010;18(7):323-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between Helicobacter pylori infection and gastric adenocarcinoma in Northern Iran.
  • Colonization of the human stomach with Helicobacter pylori induces chronic gastritis and is associated with the development of gastric and duodenal ulcers, gastric carcinoma, and gastric mucosa-associated lymphoid tissue lymphoma.
  • Infection with an H. pylori strain containing the cytotoxin-associated (cagA) gene (a marker for a pathogenicity island) may increase the risk of atrophic gastritis and gastric cancer.
  • The exact role of H. pylori in gastric carcinogenesis is still being investigated.
  • Hence, we assessed whether H. pylori infection is associated with the development of gastric adenocarcinoma in northern Iran.
  • Gastric biopsy specimens from 168 patients suffering from gastric adenocarcinoma, gastric ulcer, and non-ulcer dyspepsia were analyzed by means of the polymerase chain reaction. H. pylori was detected in the gastric mucosa of 34 (75.5%) gastric adenocarcinoma, 56 (88.8%) gastric ulcer, and 36 (60%) non-ulcer dyspepsia.
  • In patients with gastric adenocarcinoma, the cagA was less commonly found than those in noncancer patients (4/34 vs. 58/92, p < 0.05).
  • Our work suggests that although H. pylori infection is significantly associated with gastric adenocarcinoma in northern Iran, the cagA is not the dominant virulence in development of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / microbiology. Helicobacter Infections / microbiology. Helicobacter pylori / pathogenicity. Stomach Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Antigens, Bacterial / genetics. Bacterial Proteins / genetics. Female. Gastritis / microbiology. Gastritis / surgery. Humans. Iran. Male. Middle Aged. Prognosis. Stomach Ulcer / genetics. Stomach Ulcer / microbiology. Stomach Ulcer / surgery

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377133.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / cagA protein, Helicobacter pylori
  •  go-up   go-down


12. Lee J, Kang W, Lim D, Park J, Park Y, Lim H, Sohn T, Noh J, Bae J, Kim S: Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis. J Clin Oncol; 2009 May 20;27(15_suppl):4537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis.
  • : 4537 Background: Although the adjuvant chemoradiation therapy has gained popularity and has become the standard of care in patients with resected gastric cancer in U.S., the role of chemoradiation therapy after extended D2 dissection has been questioned.
  • We conducted a phase III trial to compare capecitabine/cisplatin (XP) vs XP + radiotherapy (RT) in curatively D2 resected gastric cancer patients in terms of disease free survival and overall survival.
  • METHODS: Eligibility criteria were as follows: stage Ib (T1N1, T2bN0) - IV (M1 excluded), curatively ≥ D2 resected gastric adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962988.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Gallego R, Fuster D, Ginés A, Ortín J, Ayuso JR, Momblan D, Arguis P, Conill C, Pons F, Maurel J: Usefulness of PET/CT in the diagnosis of distant metastases of potentially operable gastric adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15598

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of PET/CT in the diagnosis of distant metastases of potentially operable gastric adenocarcinoma.
  • 1) To evaluate the usefulness of Positron Emission Tomography with combined 18F-Fluorodeoxyglucose with Computed Tomography (PET/CT) in the diagnosis of distant metastases in patients with gastric adenocarcinoma (GAC) compared to spiral double contrast thoracoabdominal Computed Tomography (CT);.
  • METHODS: Thirty prospective patients (22 men, 8 women; mean age 67±11) who underwent endoscopic ultrasound and were classified as T2-3N1 or T3Nx GAC were included in this study.
  • In 1/3 patients with histopathological confirmed diagnosis of peritoneal carcinomatosis by laparoscopic findings was negative by PET/CT, and considered as a false negative case.
  • 1) PET/CT is useful in the diagnosis of distant metastases in patients with GAC 2) Further studies are needed to establish the role of PET/CT to detect peritoneal carcinomatosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962880.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Bohanes PO, Courvoisier D, Perneger T, Morel P, Huber O, Roth AD: Survival predictors in second-line chemotherapy for metastatic gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival predictors in second-line chemotherapy for metastatic gastric cancer.
  • : e15575 Background: Many patients (pts) with metastatic gastric cancer (MGC) are in good condition after first line chemotherapy (chemo) and are offered further treatment.
  • METHODS: We conducted a retrospective review of all patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma who were treated until death at our institution and died between 01.1994 and 06.2008.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962364.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Hoque E, Karim S, Hossen M, Ahmed TU: Study to see the efficacy and toxicity profile of docetaxel-based chemotherapy in advanced stomach cancer in Bangladeshi patient population. J Clin Oncol; 2009 May 20;27(15_suppl):e15687

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study to see the efficacy and toxicity profile of docetaxel-based chemotherapy in advanced stomach cancer in Bangladeshi patient population.
  • : e15687 Background: Gastric cancer is the second most common cause of cancer death worldwide.
  • In Bangladesh it is one of the major causes of cancer death.
  • Advanced gastric cancer patients have a poor prognosis of 3 to 5 months.
  • Docetaxel has shown activity against gastric cancer as monotherapy and in combination with other agents.
  • The purpose of this study was to investigate the efficacy and toxicity profile of docetaxel based chemotherapy in advanced stomach cancer in Bangladeshi patient population.
  • METHODS: From January 2004 to December 2006, thirty patients with advanced inoperable gastric cancer (Gastric or esophagogastric adenocarcinoma) were included in the study.
  • CONCLUSIONS: Adding docetaxel to CF regimen significantly improved time to tumour progression and survival rate in advanced gastric cancer patients.
  • Docetaxel in combination with Cisplatin and 5-fluorouracil is a very safe and active in patients of Bangladesh with advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962798.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Efremidis AP, Fostira F, Panopoulos C, Papademitriou K, Pistalmazian N, Tsoukalas N, Yannoukakos D: CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22218

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer.
  • : e22218 Background: Hereditary Diffuse Gastric Cancer (HDGC) syndrome is characterized by the predisposition to gastric cancer of the diffuse type and to breast cancer of the lobular type.
  • The median age of onset for diffuse gastric cancer is 38 years.
  • CDH1 mutations are highly penetrant, conferring a cumulative risk of diffuse gastric cancer of 75%.
  • RESULTS: A pathogenic mutation located on exon 7 of the CDH1 gene was identified in a female patient diagnosed with bilateral breast cancer at the age of 36.
  • She underwent bilateral mastectomy for an infiltrating ductal adenocarcinoma of the left breast and in situ lobular of the right breast.
  • At the age of 45 the patient underwent gastrectomy for diffuse type gastric adenocarcinoma.
  • She had a positive family history for breast and gastric cancer from both sides, but without meeting the absolute clinical criteria for hereditary diffuse gastric cancer syndrome.
  • The nonsense mutation found was probably maternally inherited, since the maternal grandmother was diagnosed with breast cancer at the age of 38.
  • CONCLUSIONS: The selection process of patients for genetic testing for the HDGC syndrome is not quite clear at the moment, as it is apparent that more types of breast cancer and not only lobular, can be associated with the syndrome.
  • Criteria should be more flexible in respects to the histopathology of the cancer type.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964173.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Di Fabio F, Pinto C, Rojas Llimpe F, Castellucci P, Fanti S, Mutri V, Giaquinta S, Di Tullio P, Pini S, Compagnone G, Martoni A: Early predictive value of 18F-FDG-PET assessment in advanced esophagogastric junction and gastric cancer patients treated with cetuximab-containing therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e15601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early predictive value of 18F-FDG-PET assessment in advanced esophagogastric junction and gastric cancer patients treated with cetuximab-containing therapy.
  • : e15601 Background: 18F-FDG-PET/CT (PET) was reported to predict the pathological response during preoperative chemotherapy in esophagogastric junction (GEJ) or gastric (G) cancer pts.
  • The aim of this study is to evaluate the usefulness of an early change in PET at several time-points in predicting response to cetuximab-containing therapy in pts with advanced GEJ or G cancer.
  • METHODS: We evaluated 51 pts with locally advanced/metastatic GEJ or G adenocarcinoma who underwent a first line cetuximab- treatment in two Italian phase II studies.
  • Metabolic response was defined as a decrease in maximum standard uptake value (SUV) ≥35% on the basis of our previous study (Di Fabio et al., Gastric Cancer 10:221-227, 2007).Objective response, according to RECIST criteria, was assessed by CT scan at baseline and every 6 weeks.
  • CONCLUSIONS: Our study suggests that in advanced gastric cancer pts with FDG-avid tumor the PET predicts objective response at day 42, but not at day 21.
  • Prospective trials defining the role of PET in gastric cancer are warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Power DG, Jhawer M, Feilchenfeldt JW, Kelsen DP, Shah MA: Metastatic gastroesophageal cancer and long-term survival. J Clin Oncol; 2009 May 20;27(15_suppl):4560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic gastroesophageal cancer and long-term survival.
  • : 4560 Background: Despite modest therapeutic improvements, resistance to systemic chemotherapy develops in most pts with advanced gastric/GEJ (GE) adenocarcinoma.
  • We describe clinicopathological characteristics of a large cohort of long term survivors(LTS) with metastatic GE adenocarcinoma.
  • METHODS: Our institutional database of pts with GE adenocarcinoma who received chemotherapy between 1999-2008 identified 103 pts with metastatic disease (M1) surviving >2 years from M1.
  • RESULTS: From Jan 1999-2008, 1,140 pts with metastatic GE cancer received systemic therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963060.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Guimbaud R, Bouché O, Rebischung C, Bonnetain F, Louvet C, Viret F, André T, Samalin E, Gorent J, Dutel J, Bedenne L: Planned interim analysis of the intergroup FFCD-GERCOR-FNCLCC-AERO phase III study comparing two sequences of chemotherapy in locally advanced or metastatic gastric cancers. J Clin Oncol; 2009 May 20;27(15_suppl):4533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Planned interim analysis of the intergroup FFCD-GERCOR-FNCLCC-AERO phase III study comparing two sequences of chemotherapy in locally advanced or metastatic gastric cancers.
  • : 4533 Background: There are several standard chemotherapies in locally advanced or metastatic gastric or cardia adenocarcinoma, including ECF.
  • METHODS: Patients (pts) with a gastric or cardiac adenocarcinoma, locally advanced or metastatic, not surgically curable, with a WHO PS ≤2 and evaluable or measurable lesions, were randomized (1:1) according to the following sequences: ECC (epirubicin 50 mg/m<sup>2</sup> D1+ cisplatin 60 mg/m<sup>2</sup> D1 + capecitabine 2000 mg/m<sup>2</sup> D2 to D15, every 3 weeks) in 1st line, then FOLFIRI (IRI 180 mg/m<sup>2</sup> D1, leucovorin 400 mg/m<sup>2</sup> D1, bolus 5FU 400 mg/m<sup>2</sup> D1 and continuous 5FU 2400 mg/m<sup>2</sup> in 46h, every 2 weeks) in 2<sup>nd</sup> line (Arm A) vs the reverse sequence (Arm B) with a stratification for center, PS, adjuvant treatment, site, linitis and measurable disease.
  • Pts characteristics are: PS 1: 51%, med. age 60 years, gastric 67%, M+ 88%, resected primary tumor 27% and linitis 23%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962993.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Lin R, Chen Q, Fan N, Ye Y, Guo Z, Wang X, Liu J, Chen L: Phase IIb trial of fluorouracil, leucovorin, oxaliplatin, and paclitaxel (POF) compared with fluorouracil, feucovorin, and irinotecan (IF) as first-line treatment for advanced gastric cancer (AGC). J Clin Oncol; 2009 May 20;27(15_suppl):e15642

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase IIb trial of fluorouracil, leucovorin, oxaliplatin, and paclitaxel (POF) compared with fluorouracil, feucovorin, and irinotecan (IF) as first-line treatment for advanced gastric cancer (AGC).
  • METHODS: Patients with previously untreated, advanced, unresectable, and histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction were randomly assigned to POF or IF regiment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962736.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Schuhmacher C, Schlag P, Lordick F, Hohenberger W, Heise J, Haag C, Gretschel S, Mauer ME, Lutz M, Siewert JR: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. J Clin Oncol; 2009 May 20;27(15_suppl):4510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954.
  • : 4510 Background: Combined pre- and postoperative chemotherapy improves overall survival in operable gastric cancer, although postoperative treatment is not feasible in half of the patients.
  • METHODS: Patients with locally advanced adenocarcinoma of the stomach and cardia were randomized between primary surgery or two 48-day cycles of weekly folinic acid 500 mg/m<sup>2</sup>/2h, 5-FU 2,000 mg/m<sup>2</sup>/24h plus biweekly cisplatin 50 mg/m<sup>2</sup>/1h followed by surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962708.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Manikyam Y, Hanna GG, Harte RJ, Henry PG, Houston RF, Eatock MM: Impact of socioeconomic status on treatment outcome in patients with advanced esophagogastric cancer in Northern Ireland. J Clin Oncol; 2009 May 20;27(15_suppl):e20531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of socioeconomic status on treatment outcome in patients with advanced esophagogastric cancer in Northern Ireland.
  • : e20531 Background: The survival advantage for combination chemotherapy in advanced gastroesophageal adenocarcinoma is well documented.
  • We report the impact of socioeconomic status on the outcome of ECF and ECX treatment in advanced gastroesophageal cancer patients in Northern Ireland between 2000 and 2007.
  • METHODS: All patients with advanced esophageal (O), gastric (G), or esophagogastric junction (OGJ) adenocarcinoma, receiving palliative chemotherapy from January 2000 to August 2007, were identified from our institutional database.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960981.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Moon Y, Rha S, Jeung H, Shin S, Yoo N, Roh J, Noh S, Chung H: Clinical outcome of sequential chemotherapy in metastatic and/or recurrent gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of sequential chemotherapy in metastatic and/or recurrent gastric cancer.
  • : e15521 Background: Little is known about data on subsequent chemotherapy (CTx) following 1<sup>st</sup>-line CTx in stage IV gastric cancer.
  • The purpose of this study was to analyze the natural history of stage IV gastric cancer with sequential CTx Methods: A total of 532 patients (pts) with unresectable gastric adenocarcinoma were studied.
  • Median overall survivals from diagnosis of unresectable cancer were 12.0/13.3/2.5 months for overall/CTx/BSC, respectively.
  • CONCLUSIONS: When pts with unresectable gastric cancer were managed with a strategy of maximal administration of CTx, a considerable number of pts could receive 2<sup>nd</sup> or 3<sup>rd</sup> line CTx, showing modest activity.
  • Our data on the natural history of stage IV gastric cancer with sequential CTx may suggest that clinical trials can be performed in a 2<sup>nd</sup> or 3<sup>rd</sup> line setting as well.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962260.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Servarayan CM, Chandramohan A, Datta D, Manickavasagam K: p53 and its influence in adenocarcinoma stomach. J Clin Oncol; 2009 May 20;27(15_suppl):e15685

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and its influence in adenocarcinoma stomach.
  • : e15685 Background: Gastric cancer is the second most common cause of the malignancy in the world after lung cancer.
  • Various pathogenesis have been given for the adenocarcinoma, like mutation in the E-catherin gene, amplification of COX-2, HGF/ SF, VEGF; deletion of FHIT, APC, p53 but none have provided a definite target for treatment.
  • METHODS: This is a immunohistochemical prospective experiment study done on 76 cases of Gastric Adenocarcinoma.The location of the tumors were recorded as in the proximal stomach (fundus and body) and distal stomach (antrum, prepylorus, and pylorus).
  • 33 out of 60 (55%)of the males and 8 out of 16 (50%) females were reported of having gastric adenocarcinoma with p53expression.
  • The histology of the tissue samples from the gastric adenocarcinoma patients had following relationship with the p53 immunoreactivity, 20 out of 37 cases(54.05%) of the well differentiated,7 out of 17 cases (41.18% )of the moderately differentiated, and and 13 out of 21 cases(61.90%) of the poorly differentiated gastric adenocarcinoma showed positive immunoreactivity.
  • 15 out of 33 cases (45.45%)were localized to the proximal stomach and 30 out of 52 cases (57.69%)were localized to the distal stomach.
  • 52.63 % of the non-mucinous type of gastric adenocarcinoma showed positive p53 immunoreactivity.
  • The mutation is more marked in the poorly differentiated gastric adenocarcinoma.
  • The antral, pylorus,and the prepyloric parts of the stomach( the distal stomach) are more prone for mutated p53 induced adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kunz PL, de Bruin MA, Balise RR, Fisher GA, Ford JM: Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. J Clin Oncol; 2009 May 20;27(15_suppl):e15686

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience.
  • : e15686 Background: There is no single standard chemotherapy regimen for the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • At Stanford Cancer Center (SCC) we regularly use a regimen of carboplatin and 5- fluorouracil (CF) or carboplatin and capecitabine (CX) for the treatment of these patients.
  • METHODS: A single institution retrospective review of patients with metastatic gastric and GEJ adenocarcinoma treated with CF or CX was conducted.
  • Median age at diagnosis was 66 years.
  • Twenty-nine (64%) had gastric and 16 (36%) had GEJ cancers.
  • Twenty-nine (64%) had poorly differentiated and 10 (22%) had moderately differentiated adenocarcinomas; 13 (29%) had signet ring features.
  • CONCLUSIONS: CF and CX are well tolerated and yield acceptable outcomes in high-risk metastatic gastric and gastroesophageal junction cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962796.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ajani JA, Rodriquez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S: Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. J Clin Oncol; 2009 May 20;27(15_suppl):4511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses.
  • METHODS: 1,053 (1,029 treated; CS=521/CF=508) patients with untreated, advanced gastric/gastroesophageal adenocarcinoma were randomized to either S-1 (25 mg/m<sup>2</sup> bid, d 1-21)/cisplatin (75 mg/m<sup>2</sup> d 1) q 28 d or 5-FU (1,000 mg/m<sup>2</sup>/d 5-d infusion)/cisplatin (100 mg/m<sup>2</sup> d 1) q 28 d.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962707.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. El-Rayes BF, Patel B, Zalupski M, Hammad N, Shields A, Heilbrun L, Venkatramanamoorthy R, Philip P: A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer.
  • : 4563 Background: VEGF (vascular endothelial growth factor) has a central role in angiogenesis, tumor growth and metastasis of gastric cancer.
  • METHODS: The primary endpoint was time to progression (TTP) in patients with locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction treated with docetaxel, oxaliplatin and bevacizumab.
  • RESULTS: A total of 23 patients (median age 57, males 70%, gastric 52%) were enrolled on the study.
  • At this time, bevacizumab should not be used in gastric or gastroesophageal junction cancers outside of a clinical trial until its safety is well established.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963057.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Kakeji Y, Mizokami K, Sumiyoshi Y, Yoshinaga K, Saeki H, Tokunaga E, Endo K, Morita M, Kitao H, Emi Y, Maehara Y: The prognostic impact of hypoxia-inducible factor-1α and VEGF, IGF-2, p21, p53 expression in gastric adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic impact of hypoxia-inducible factor-1α and VEGF, IGF-2, p21, p53 expression in gastric adenocarcinoma.
  • The clinicopathological characteristics of human gastric cancer and the clinical outcomes were analyzed to investigate the effects of the expression of hypoxia-inducible factor1α (HIF-1α) and some related proteins, such as, vascular endothelial growth factor (VEGF), insulin-like growth factor-2 (IGF-2), p21, and p53 on the prognosis of human gastric cancer.
  • METHODS: The expressions of HIF-1α, VEGF, IGF-2, p21, and p53 proteins were determined by immunohistochemistry in 216 specimens of primary gastric cancer.
  • In addition, the HIF-1α expression positively correlated with the tumor size and depth of invasion, while it was also more frequent in tumors with lymphatic invasion and undifferentiated adenocarcinomas.
  • A multivariate Cox regression analysis showed the depth of invasion, lymph node metastasis, and HIF-1α positivity to all be independent prognostic factors in patients with gastric cancer.
  • CONCLUSIONS: Based on the above findings, HIF-1α is therefore considered to be a useful independent prognostic factor in gastric cancer, and the combination of a HIF-1α protein overexpression with the loss of p21 expression or nonfunctional p53 thus tends to indicate a dismal prognosis.
  • Controlling hypoxia, especially in the HIF-1α pathways, may therefore hold the key to a greater individualization of therapy and also lead to the development of new treatments for patients with gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963078.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Thuss-Patience PC, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, Schumacher G, Gebauer B, Maier V, Reichardt P: Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol; 2009 May 20;27(15_suppl):4540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
  • : 4540 Background: Up to now the value of 2<sup>nd</sup>-line therapy for metastatic gastric cancer is unclear.
  • In this randomized phase III study we compared irinotecan to BSC to evaluate the value of 2<sup>nd</sup>- line chemotherapy for gastric cancer.
  • Eligibility: Metastatic or locally advanced gastro-esophageal junction or gastric adenocarcinoma.
  • CONCLUSIONS: To our knowledge this is the first randomized phase III study investigating 2<sup>nd</sup>- line chemotherapy in gastric cancer.
  • 2<sup>nd</sup>-line chemotherapy can now be considered as a proven option in gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963017.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Pera M, Gallego R, Martin-Richard M, Montagut C, Iglesias M, Conill C, Balaguer C, Petriz L, Momblan D, Maurel J: Phase II study with preoperative oxaliplatin (O), cisplatin (P), 5-fluorouracil (F) (OPF) and radiation (XRT) in patients with esophageal (ES), gastroesophageal (GE), and gastric (G) cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15612

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study with preoperative oxaliplatin (O), cisplatin (P), 5-fluorouracil (F) (OPF) and radiation (XRT) in patients with esophageal (ES), gastroesophageal (GE), and gastric (G) cancer.
  • : e15612 Background: A phase I study showed the feasibility of the triplet combination (OPF) with XRT in ES and GE cancer (Maurel et al, IJRBOP, 2005).
  • METHODS: Enrolled pts had resectable, high-risk (HR) based on endoscopic ultrasonography (EUS) (uT3, uN1 or uT4 if deemed resectable) ES, GE and G cancer.
  • Eligibility criteria: squamous cell or adenocarcinoma of the ES, GE or G cancer and ECOG Performance status (PS) 0-1.
  • Laparoscopic staging was mandatory for pts with ES, GE and G adenocarcinoma.
  • CONCLUSIONS: Although in the whole group pCR, PFS and OS does not appear superior to results achieved in other trials with preoperative P/F/XRT in HR pts, the OPF regimen seems specially active in ES cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962712.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Kelsen D, Jhawer M, Ilson D, Tse A, Randazzo J, Robinson E, Capanu M, Shah MA: Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial. J Clin Oncol; 2009 May 20;27(15_suppl):4512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial.
  • : 4512 Background: Metastatic GE cancer is an aggressive disease with poor patient (pt) outcomes.
  • The addition of BEV to chemotherapy has improved survival in several solid tumors, and has demonstrated encouraging activity in GE cancer (Shah et al, JCO 2006).
  • We report mature tolerability and efficacy results of mDCF+BEV in GE cancer, with an emphasis on prolonged pt survival.
  • RESULTS: Pt enrollment has completed: median age 57(range 29-74), median KPS 80% (70-100), M:F 32:12, gastric/GEJ/esophagus 22:17:5.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962705.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Fahlke J, Ridwelski K, Florschuetz A, Kettner E, Leithaeuser M, Kroehning H, Stuebs P, Zierau K, Lippert H: Cetuximab plus docetaxel-cisplatin (DC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e15592

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab plus docetaxel-cisplatin (DC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase II study.
  • : e15592 Background: Based on promising published data, this multicenter, phase II study was initiated to investigate a combined treatment using DC and cetuximab in the first-line setting for patients with gastric cancer.
  • METHODS: Patients aged 18-75 years with stage III (T4, nonresectable) or stage IV gastric cancer, ECOG performance status (PS) ≤2, and life expectancy ≥3 months were recruited to receive cetuximab (400 mg/m<sup>2</sup> on day 1 then 250 mg/m<sup>2</sup> q1w) and DC (D 75 mg/m<sup>2</sup> and C 75 mg/m<sup>2</sup>; both as 1-h infusions on day 1 and then q3w).
  • RESULTS: Preliminary data are available for 30 patients; median age 64 [range: 40-73] years; median ECOG PS 1 [range: 0-2]; adenocarcinoma 87%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962888.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Younger people with gastric cancer have poor prognosis. Nurs Stand; 2009 Aug 05;23(48):14-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Younger people with gastric cancer have poor prognosis.
  • : Patients aged 35 and under who present with gastric adenocarcinoma are likely to have a more aggressive tumour type with both locally advanced and metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28038534.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Nakayama N, Koizumi W, Sasaki T, Tanabe S, Nishimura K, Higuchi K, Takagi S, Katada C, Azuma M, Saigenji K: Phase II study of combination therapy with docetaxel, cisplatin, and S-1 (DCS) for advanced gastric cancer: (KDOG 0601). J Clin Oncol; 2009 May 20;27(15_suppl):4555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of combination therapy with docetaxel, cisplatin, and S-1 (DCS) for advanced gastric cancer: (KDOG 0601).
  • : 4555 Background: Our previous phase I study (Oncology 2008, 75:1-7) provided evidence that combination chemotherapy with docetaxel, cisplatin, and S-1 (DCS) is effective and well tolerated in patients with advanced gastric cancer.
  • The present multicenter phase II study was conducted to confirm the efficacy and toxicity of DCS in advanced gastric cancer.
  • METHODS: Eligibility criteria included a histologically proved diagnosis of gastric adenocarcinoma with at least one measurable metastatic lesion, no previous treatment for gastric cancer except for surgery, an ECOG performance status of 0 to 2, and adequate organ function.
  • CONCLUSIONS: DCS was a well-tolerated regimen with a high response rate in patients with advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963030.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Lu M, Shen L: Recurrence patterns of Chinese patients with gastric cancer after complete resection. J Clin Oncol; 2009 May 20;27(15_suppl):e15667

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence patterns of Chinese patients with gastric cancer after complete resection.
  • : e15667 Background: Recurrence after radical resection was the most important factor that influence the prognosis of patients with gastric adenocarcinoma.
  • Focusing on the clinicopathologic features and recurrence patterns, this study aims to find the characteristics of recurrence pattern and the predictive factors of gastric cancer patients in China.
  • METHODS: This is a retrospective analysis of the gastric adenocarcinoma patients who accepted adjuvant treatment and follow up in our medical department after R0 resection.
  • Locoregional recurrence was defined as dominant masses in the gastric bed, regional nodes or anastomotic recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962752.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. de Bruin MA, Kunz PL, Sharma VB, Norton JA, Bastidas J, Chang DT, Koong AC, Koong AC, Balise RR, Ford JM, Fisher GA: Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. J Clin Oncol; 2009 May 20;27(15_suppl):e15674

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience.
  • : e15674 Background: The standard of care for the adjuvant treatment of resected gastric or gastroesophageal junction (GEJ) adenocarcinoma in the U.S. is post-operative 5FU and radiotherapy per the MacDonald regimen.
  • At Stanford Cancer Center (SCC) we have adopted a modified regimen of chemoradiotherapy using carboplatin and a fluoropyrimidine.
  • METHODS: A retrospective review was performed of patients at SCC with T2-T4 or node positive gastric or GEJ cancer who underwent surgery with curative intent, and then received the following treatment.
  • At week 8, infusional 5FU or capecitabine was combined with external beam radiotherapy to the gastric bed for five weeks (total 4,500 cGy).
  • Median age at diagnosis was 57 years.
  • Thirty-nine had gastric and 10 had GEJ cancers.
  • CONCLUSIONS: Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine after curative resection of gastric and GEJ cancer was well tolerated and yielded survival results similar to historical data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962823.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Kim S, Kim J, Chae Y, Sohn S, Moon J, Kang B, Chung H, Yu W, Baek J: Prognostic impact of the NFKB1 insertion/deletion promoter polymorphism on survival in patients with surgically resected gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15638

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of the NFKB1 insertion/deletion promoter polymorphism on survival in patients with surgically resected gastric cancer.
  • : e15638 Background: The present study analyzed the functional insertion/deletion polymorphism in the promoter region of NKFB1 gene and their impact on the prognosis for patients with gastric adenocarcinoma.
  • METHODS: Five hundred and three consecutive patients with surgically resected gastric adenocarcinoma were enrolled in the present study.
  • The multivariate survival analysis showed no association between the NFKB1 -94 insertion/deletion promoter polymorphism and the disease-free survival or overall survival of the patients with gastric cancer.
  • CONCLUSIONS: The functional NFKB1 promoter polymorphism was not found to be a prognostic marker for Korean patients with surgically resected gastric adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Leichman L, Goldman BH, Benedetti JK, Billingsley KG, Thomas CR, Iqbal S, Lenz H, Blanke C, Gold PJ, Corless CL: Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). J Clin Oncol; 2009 May 20;27(15_suppl):4513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356).
  • METHODS: Eligibility: clinical stage II/III EA, ≥ 18 years, Zubrod PS ≤ 2, standard hematologic/non-hematologic values, and tumor < 2 cm into the gastric cardia.
  • 9 PTS (10%) had in-situ cancer or T1N0M0.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962704.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Mohri Y, Kageyama S, Mohri T, Tanaka K, Ohi M, Yokoe T, Kusunoki M: Macrophage migration inhibitory factor and long-term survival in gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophage migration inhibitory factor and long-term survival in gastric cancer.
  • : e15525 Background: Our study aimed to evaluate whether pretherapeutic serum macrophage migration inhibitory factor (MIF) is an independent factor predicting long-term survival in gastric cancer.
  • Gastric cancer is the second leading cause of cancer-related deaths worldwide, but no satisfactory tumor marker exists.
  • We recently found serum MIF expression was progressively increased in gastric cancer.
  • METHODS: One hundred five patients, 73 men and 32 women, mean (±SD) age 63±14 years, with histologically proven gastric adenocarcinoma were included in the study.
  • CONCLUSIONS: The serum level of MIF is a potentially valuable pretherapeutic prognostic factor in patients with gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962256.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, Nasu J, Nakamura K, Fukuda H, Ohtsu A: Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). J Clin Oncol; 2009 May 20;27(15_suppl):4545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106).
  • : 4545 Background: Gastric cancer (GC) with peritoneal metastasis (PM) often complicates ascites or intestinal stenosis and the prognosis is still poor.
  • Anti-cancer drugs generally can not be administered for such patients (pts) due to the risk of serious and prolonged adverse events.
  • METHODS: Eligibility criteria included pts with histologically proven gastric adenocarcinoma; inoperable or recurrent GC; PM with radiologically confirmed intestinal stenosis or ascites; 20-75 years old; PS 0-2; no prior treatment except surgery or adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Oh S, Kim S, Kwon H, Kim H, Hwang I, Kang J, Lee S, Lee J, Kang W: Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases.
  • : e15658 Background: Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer.
  • The most common cancers involving the leptomeninges are breast and lung cancer.
  • However, gastric adenocarcinoma has been rarely reported with leptomeningeal carcinomatosis (LMC).
  • METHODS: We analyzed 54 cases of cytological confirmed gastric LMC at 4 institutions from 1994 to 2007.
  • The majority of patients had advanced disease at the initial diagnosis of gastric cancer.
  • The clinical or pathologic TNM stages of the primary gastric cancer were IV in 38 patients (70%).
  • The median interval from the diagnosis of the primary malignancy to the diagnosis of LMC was 6.3 months (range, 0 - 73.1 months).
  • Median OS duration from diagnosis of LMC was 6.7 weeks (95% CI; 4.3-9.1 weeks).
  • CONCLUSIONS: Although gastric LMC has dismal prognosis, IT and IV chemotherapy could be help to extend survival duration of gastric LMC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962774.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah MA, MET111643 Investigators and GlaxoSmithKline: Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study.
  • METHODS: Pts with distal esophagus, GE junction or stomach adenocarcinoma, 0-2 prior chemotherapy regimens, adequate organ function, measurable disease, and ECOG PS 0-2 are sequentially enrolled in 2 cohorts:.
  • Single agent GSK089 demonstrates minimal antitumor activity in a cMET-unselected gastric population on the 5 on/9 off schedule.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962690.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Glehen O, Elias D, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Association Française de Chirurgie: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from digestive or primitive origin: A multi-institutional study of 1,290 patients. J Clin Oncol; 2009 May 20;27(15_suppl):4102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The principal etiologies of PC were colorectal adenocarcinoma (N=523), pseudomyxoma peritonei (N=301), gastric adenocarcinoma (N=159), peritoneal mesothelioma (N=88), and appendiceal adenocarcinoma (N=50).
  • The overall median survival was 34 months: 30 months for colorectal PC, not reached for pseudomyxoma peritonei, 9 months for gastric PC, 41 months for peritoneal mesothelioma, and 77 months for PC from appendiceal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961196.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Kanzler S, Trarbach T, Seufferlein T, Kubicka S, Lordick F, Geissler M, Daum S, Galle PR, Moehler M, German Arbeitsgemeinschaft Internistische Onkologie (AIO): Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study.
  • : 4534 Background: Cetuximab has demonstrated high efficacy in combination with irinotecan-based therapies in metastatic colorectal cancer and irinotecan/folinic acid/5-FU (IF) may be an effective alternative to cisplatin-based regimens in advanced gastric cancer.
  • We therefore conducted a phase II AIO study to evaluate the tolerability and efficacy of cetuximab combined with IF as first-line treatment in patients with advanced gastric cancer.
  • METHODS: Patients (pts) were eligible with untreated adenocarcinoma of the stomach or oesophagogastric junction, with ECOG performance status (PS) < 2, measurable lesions and adequate organ functions.
  • RESULTS: Between Aug 2006 and Sep 2007, 49 pts were enrolled: 71% were males, median age was 63 years (range 33-77), median PS was 0 (65% pts), and 69% of pts and 31% of pts had gastric and oesophagogastric junction carcinomas, respectively.
  • Cetuximab combined with chemotherapy in advanced or metastatic gastric cancer is under further investigation in an ongoing phase III trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962992.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Woell E, Greil R, Eisterer W, Fridrik M, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Thaler J: Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT). J Clin Oncol; 2009 May 20;27(15_suppl):4538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT).
  • : 4538 Background: Patients (pts.) suffering from advanced gastric cancer have still a poor prognosis and treatment options are limited.
  • In our previous phase II trial (AGMT-Gastric-1) we could show that the combination of oxaliplatin and irinotecan was well tolerated and showed an objective response rate of 58% (Anticancer Res 28:2901-2906, 2008).
  • 51 patients with histological proven unresectable and/or metastatic gastric adenocarcinoma were treated in a first line setting.
  • CONCLUSIONS: The combination of oxaliplatin and irinotecan with cetuximab is feasible, safe and active in advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Myint R, Batus M, Bonomi P, Gattuso P, Warren WH, Liptay M, Faber P, Basu S, Xu X, Kim AW: Xanthine oxidoreductase and chemosensitivity in non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xanthine oxidoreductase and chemosensitivity in non-small cell lung cancer.
  • Clin Cancer Res.
  • 2005;11:4372-4381) and gastric cancers (Linder et al.
  • The goal of our study was to show that decreased XOR expression was associated with decreased survival in non-small cell lung cancer (NSCLC).
  • These included 41 adenocarcinoma, 31 squamous cell, 8 poorly/moderately differentiated, and 2 bronchioloalveolar.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963201.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Goel R, Chen E, Welch S, Laurie S, Siu L, Jonker D, Srinivasan R, Wang L, Ivy P, Oza A, Princess Margaret Hospital Phase II Consortium: Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These two drugs exhibit synergistic cytotoxic effects against the H522 non-small cell lung cancer (NSCLC) xenografts.
  • RESULTS: Patient characteristics: male 11/female 10; median age 59 (range 28-84); performance status 0 /1/2: n=1/13/7; prior chemotherapy 21, prior radiotherapy 7, prior immunotherapy 1; tumour types: ovarian cancer 3, endometrial cancer 3, NSCLC 3, gastric/esophageal adenocarcinoma 3, miscellaneous 9.
  • RESPONSE: partial response 1 (ovarian cancer), stable 8 [minor response 4 (NSCLC 2, endometrial cancer 1, head and neck cancer 1)], progression 8, inevaluable 4.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961270.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Boukovinas I, Androulakis N, Polyzos A, Vardakis N, Amarantidis K, Bozionelou V, Kouroussis C, Giassas S, Christophyllakis C, Mavroudis D: A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer.
  • : 4536 Background: To compare the efficacy and tolerance of two oxaliplatin-based regimens as first-line treatment of advanced gastric cancer.
  • METHODS: Chemotherapy-naïve patients with measurable recurrent or metastatic gastric adenocarcinoma, PS (ECOG) 0-2 and adequate organ functions were randomly assigned to receive either irinotecan 200mg/m2 and oxaliplatin 80mg/m2 (IO), every 21 days or oxaliplatin 85mg/m<sup>2</sup> on day 1, 5-FU 400 mg/m<sup>2</sup> (over 1 hour infusion) + 600mg/m<sup>2</sup> (over 22 hours infusion) on days 1 and 2, leucovorin (LV) 200mg/m<sup>2</sup> on days 1 and 2 (FOLFOX4) every 2 weeks.
  • CONCLUSIONS: Both regimens are well tolerated and active in advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962990.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Aziz SA, Banday MA, Mir MH: Comparative efficacy of adjuvant chemoradiation versus chemotherapy in surgically resected adenocarcinoma of stomach. J Clin Oncol; 2009 May 20;27(15_suppl):e15639

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative efficacy of adjuvant chemoradiation versus chemotherapy in surgically resected adenocarcinoma of stomach.
  • : e15639 Background: Outcome of carcinoma of stomach has not changed over the past decades and surgery remains the time tested primary modality of treatment.
  • The present study focuses to compare the efficacy of adjuvant chemoradiation Vs Chemotherapy alone in surgically resected adenocarcinoma of stomach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962750.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Yoon J, Cho S, Bae W, Hwang J, Shim H, Chung I: Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer.
  • : e15599 Background: The role of the second line chemotherapy in advanced gastric cancer was not clear, but possibility of prolongation of survival is open question.
  • Irinotecan is promising agents in gastric cancer and this phase II study evaluated the efficacy and safety of combination chemotherapy with irinotecan, high dose of 5-fluorouracil (5-FU) and leucovorin in taxane and cisplatin based chemotherapy refractory metastatic gastric cancer.
  • METHODS: Eligible criteria were as followed; histologic confirmed adenocarcinoma of stomach, previously treated with taxane and cisplatin, age≥18, Eastern Clinical Oncology Group (ECOG) performance status of 1 or less, adequate organ function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Matsusaka S, Chin K, Mizunuma N, Ogura M, Suenaga M, Shinozaki E, Terui Y, Hatake K: Circulating tumor cells (CTCs) as a surrogate marker for determining response to chemotherapy in advanced gastric cancer (AGC). J Clin Oncol; 2009 May 20;27(15_suppl):4600

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells (CTCs) as a surrogate marker for determining response to chemotherapy in advanced gastric cancer (AGC).
  • : 4600 Background: The purpose of this study was to quantitate circulating tumor cells (CTCs) in advanced gastric cancer (AGC) patients and to demonstrate the role of CTCs in cancer therapy.
  • METHODS: Eligibility criteria: PS (ECOG) of 0 to 2; histopathology of adenocarcinoma; adequate major organ functions.
  • RESULTS: From November 2007 to September 2008, thirty patients with unresectable or recurrent gastric cancer were enrolled onto a prospective study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964156.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Cho S, Lee S, Hwang J, Bae W, Shim H, Park C, Park M, Chung I: Phase II study of S-1 monotherapy in taxane, cisplatin refractory gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of S-1 monotherapy in taxane, cisplatin refractory gastric cancer.
  • In previous study, S-1 demonstrated promising activity which is comparable to combination chemotherapy in advanced gastric cancer.
  • This phase II study evaluated the efficacy and safety of S-1 salvage chemotherapy, in patients with taxane and cisplatin refractory gastric cancer.
  • METHODS: Patients were eligible if they had histologically documented gastric adenocarcinoma previously treated with taxane (docetaxel or paclitaxel) and cisplatin; age≥18; Eastern Clinical Oncology Group (ECOG) performance status of 2 or less; adequate organ function; no evidence of gastrointestinal obstruction or passage disturbance.
  • CONCLUSIONS: This results showed that S-1 monotherapy was active and safe salvage chemotherapy in patients with advanced gastric cancer previously treated with taxane and cisplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963034.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Lee JH, Shim JS, Lee JS, Kim JK, Yang IS, Chung MS, Kim KH: Inhibition of pathogenic bacterial adhesion by acidic polysaccharide from green tea (Camellia sinensis). J Agric Food Chem; 2006 Nov 15;54(23):8717-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inhibitory effects of CS-F2 on the adhesion of H. pylori to AGS adenocarcinoma gastric epithelial cells, or P. acnes and S. aureus to NIH 3T3 fibroblast cells, were further assessed resulting in MIC values between 0.063 and 0.13 mg/mL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090112.001).
  • [ISSN] 0021-8561
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Polysaccharides
  •  go-up   go-down


54. Ma XL, Sun HJ, Wang YS, Huang SH, Xie JW, Zhang HW: Study of Sonic hedgehog signaling pathway related molecules in gastric carcinoma. World J Gastroenterol; 2006 Jul 7;12(25):3965-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of Sonic hedgehog signaling pathway related molecules in gastric carcinoma.
  • AIM: To study the expression of Sonic hedgehog pathway-related molecules, Sonic hedgehog (Shh) and Gli1 in gastric carcinoma.
  • METHODS: Expression of Shh in 56 gastric specimens including non-cancerous gastric tissues, gastric adenocarcinoma, gastric squamous cell carcinoma was detected by RT-PCR, in situ hybridization and immunohistochemistry.
  • RESULTS: The positive rate of Shh and Gli1 expression was 0.0%, 0.0% in non-cancerous gastric tissues while it was 66.7%, 57.8% respectively in gastric adenocarcinoma, and 100%, 100% respectively in gastric squamous cell carcinoma.
  • There was a significant difference between the non-cancerous gastric tissues and gastric carcinoma (P<0.05).
  • Elevated expression of Shh and Gli1 in gastric tubular adenocarcinoma was associated with poorly differentiated tumors while the expression was absent in gastric mucinous adenocarcinoma.
  • CONCLUSION: The elevated expression of Shh and Gli1 in gastric adenocarcinoma and gastric squamous cell carcinoma shows the involvement of activated Shh signaling in the cellular proliferation of gastric carcinogenesis.
  • It suggests Shh signaling gene may be a new and good target gene for gastric tumor diagnosis and therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Stomach Neoplasms / metabolism. Trans-Activators / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Hedgehog Proteins. Humans. RNA, Messenger / metabolism. Signal Transduction. Stomach / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2000 Jun;127(12):2763-72 [10821773.001]
  • [Cites] Cancer Lett. 2005 Sep 28;227(2):99-104 [16112412.001]
  • [Cites] Nat Immunol. 2001 Feb;2(2):172-80 [11175816.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Nat Neurosci. 2002 Feb;5(2):103-10 [11788837.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):892-7 [12192414.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Gut. 2002 Nov;51(5):628-33 [12377798.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1829-37 [14691301.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):407-13 [8837770.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):58-61 [9731532.001]
  • [Cites] Neuron. 1999 Jan;22(1):103-14 [10027293.001]
  • [Cites] J Mol Med (Berl). 1999 Jun;77(6):459-68 [10475061.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(23):9055-67 [11074003.001]
  • (PMID = 16810741.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC4087703
  •  go-up   go-down


55. Tsuburaya A, Narahara H, Imamura H, Hatake K, Imamoto H, Esaki T, Kato M, Furukawa H, Hamada C, Sakata Y, GC0301/TOP-002 Study Group: Updated result on the 2.5-year follow-up of GC0301/TOP-002: Randomized phase III study of irinotecan plus S-1 (IRI-S) versus S-1 alone as first-line treatment for advanced gastric cancer (AGC). J Clin Oncol; 2009 May 20;27(15_suppl):4544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated result on the 2.5-year follow-up of GC0301/TOP-002: Randomized phase III study of irinotecan plus S-1 (IRI-S) versus S-1 alone as first-line treatment for advanced gastric cancer (AGC).
  • We need more considering predictive factors, because the gastric cancer is heterogeneous adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963013.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Hayashi K, Sengoku N, Kosaka Y, Enomoto T, Kajita S, Kondo Y, Kuranami M, Watanabe M: [A long-term survival case of progressive breast cancer detected in gastric metastasis]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2756-9
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of progressive breast cancer detected in gastric metastasis].
  • A 51-year-old postmenopausal woman was diagnosed as having adenocarcinoma (gastric cancer type 4) from gastric biopsy by upper endoscopy.
  • After gastric biopsy, tissues are stained by ER and PgR in immunohistochemistry.
  • The diagnosis was modified from gastric cancer to T2N1M1, stage IV left breast cancer, accompanied by a treatment.
  • Metastatic gastric tumors simulating type 4 advanced gastric cancer (MGTS type 4) and invasive lobular carcinoma are known to have an unfavorable prognosis.
  • We should keep in mind a possibility of gastric metastasis of breast cancer, when consulting a female patient with gastric cancer type 4.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Stomach Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224703.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


57. Bazuro GE, Torino F, Gasparini G, Capurso L: Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all? Minerva Gastroenterol Dietol; 2008 Dec;54(4):429-44
Hazardous Substances Data Bank. MESALAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all?
  • Despite the general progress of the last two decades in oncogenesis mechanism comprehension, in screening and surveillance programs, in technological support to diagnosis and in treatment protocols, the long-term survival of gastrointestinal (GI) cancer patients is not substantially changed.
  • Therefore chemoprevention strategies still appear as a possible alternative to screening and surveillance programs in reducing the incidence and the mortality for GI cancer, at an acceptable cost/effectiveness ratio.
  • The present review is focused on three GI cancers: esophageal adenocarcinoma, gastric cancer and colorectal cancer and their respective precarcinogenic lesions.
  • The authors examine, for each neoplasia, the available chemopreventive agents, their mechanism of action in preventing cancer, the potential targets in the cell growth process, the cost/effectiveness ratio and, whenever present in literature, a comparison with other cancer prevention strategies.
  • The authors conclude that, at present, with the available agents, chemoprevention is not indicated for all patients at low or moderate risk for GI cancer, and should not be considered as a substitute for endoscopic surveillance.
  • In future more specific agents and combined therapies should be tested in specific group of patients identified by their genomic susceptibility to develop cancer and responsiveness to therapy.
  • [MeSH-major] Adenocarcinoma / prevention & control. Gastrointestinal Neoplasms / prevention & control
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Colorectal Neoplasms / prevention & control. Esophageal Neoplasms / prevention & control. Humans. Mesalamine / therapeutic use. Probiotics / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Stomach Neoplasms / prevention & control

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047983.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 4Q81I59GXC / Mesalamine; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; R16CO5Y76E / Aspirin
  • [Number-of-references] 102
  •  go-up   go-down


58. Xue LY, Zou SM, Zheng S, Xie YQ, Wen P, Liu XY, Lin DM, Lü N: [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance]. Zhonghua Zhong Liu Za Zhi; 2010 Nov;32(11):838-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance].
  • OBJECTIVE: To investigate and analyze the expression of fascin and CK14 in multiple histological types of cancer and to explore the potential value of the two proteins as markers in diagnosis and differential diagnosis of various cancer types.
  • METHODS: Tissue microarray containing esophageal squamous cell carcinoma (SCC), lung SCC, larynx SCC, uterine cervical SCC, SCC of external genital organs, lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, heptocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating ductal carcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma and renal clear cell carcinoma, 30 cases each, as well as corresponding normal controls was constructed.
  • In lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating dutal adenocarcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma and renal clear cell carcinoma, the positive rates were 38.0%, 23.3%, 14.3%, 10.3%, 73.3%, 13.3%, 6.7%, 60.0%, 66.7% and 10.0%, respectively.
  • It was weak and focal in lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating dutal adenocarcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma, and renal clear cell carcinoma, with a positive rate of 13.3%, 13.3%, 20.7%, 41.4%, 46.7%, 6.7%, 40.0%, 13.3%, 20.0% and 6.7%, respectively.
  • Combination of fascin and CK14 should be a valuable marker in diagnosis and differential diagnosis of carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Carrier Proteins / metabolism. Keratin-14 / metabolism. Laryngeal Neoplasms / metabolism. Microfilament Proteins / metabolism
  • [MeSH-minor] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21223690.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Keratin-14; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


59. Chen H, Cen P, Li JQ, Lin YG, Jiang HX, Tang GD, Zang N, Feng ZB, Su QJ, Xiao X: [Vasoactive intestinal peptide expression and its clinical significance in gastric adenocarcinoma]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Dec;22(6):452-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vasoactive intestinal peptide expression and its clinical significance in gastric adenocarcinoma].
  • OBJECTIVE: To investigate the expression of vasoactive intestinal peptide (VIP) in gastric adenocarcinoma, and to evaluate the correlation of VIP level with clinical pathologic parameters.
  • METHODS: The level of VIP in sera from gastric adenocarcinoma patients and healthy people was investigated by ELISA.
  • Moreover, the differential gene expression between gastric adenocarcinoma, gastric dysplasia, and the corresponding normal gastric mucosa were determined by RT-PCR.
  • Western Blot was also used to measure the expression of VIP in the gastric adenocarcinoma and the normal gastric mucosa.
  • RESULTS: The serum level of VIP was (5.794 +/- 0.014) ng/ ml in normal control and was (14.437 +/- 0.825) ng/ml in gastric adenocarcinoma patients, showing significant difference (P < 0.05).
  • Meanwhile,the V/B of gastric adenocarcinoma tissues was greater than that of gastric dysplasia and the corresponding normal gastric mucosa (P <0.01), the values of V/B were 1.5261 +/- 0.3028, 0.9334 +/- 0.2872,and 0.9051 +/- 0.2794, respectively.
  • The values of V/B between normal gastric mucosa and gastric dysplasia were not different significantly (P > 0.05).
  • The VIP mRNA expression was higher in gastric adenocarcinoma with lymph node metastasis than that without lymph node matastsis (P < 0.05).
  • The VIP protein expression of the gastric adenocarcinoma tissues was greater than that of normal control.
  • CONCLUSION: This findings provide a direct evidence to support the possibility that VIP play a cofactor role in the pathogenesis of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood. Gastric Mucosa / metabolism. Stomach Neoplasms / blood. Vasoactive Intestinal Peptide / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544643.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 37221-79-7 / Vasoactive Intestinal Peptide
  •  go-up   go-down


60. Chadha MK, Fakih MG, Tian L, Mashtare T, Nesline M, Davis W, Silliman C, Trump DL: Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients.
  • We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to flu vaccine in cancer patients.
  • METHODS: Cancer patients at Roswell Park Cancer Institute were offered trivalent (H1N1, H3N2, B/Malaysia) Flu vaccine (Fluzone, 2006-7) and sera collected for hemagglutination inhibition (HI) assay titers.
  • Logistic regression model was used using other covariates such as age, gender, cancer type, and chemotherapy (CT) as controls.
  • RESULTS: 85 patients with colorectal, 35 with prostate, 1 with anal and 1 with gastric adenocarcinoma participated in the study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961109.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Ren JS, Kamangar F, Qiao YL, Taylor PR, Liang H, Dawsey SM, Liu B, Fan JH, Abnet CC: Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut; 2009 May;58(5):636-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort.
  • OBJECTIVE: Low serum pepsinogen I (PGI) and low pepsinogen I/pepsinogen II ratio (PGI/II ratio) are markers of gastric fundic atrophy.
  • We aimed to prospectively test the association between serum PGI/II ratio and risks of gastric non-cardia adenocarcinoma, gastric cardia adenocarcinoma, and oesophageal squamous cell carcinoma (OSCC).
  • MAIN OUTCOME MEASURES: Adjusted hazard ratios and 95% confidence intervals for the association between serum PGI/II ratio and cancer risk.
  • RESULTS: Compared to subjects with PGI/II ratio of >4, those with <or=4 had hazard ratios (HRs) (95% CIs) of 2.72 (1.77 to 4.20) and 2.12 (1.42 to 3.16) for non-cardia and cardia gastric adenocarcinomas, respectively.
  • The nonlinear continuous models suggested that any single cut point collapsed subjects with dissimilar gastric adenocarcinoma risks, and that using cut points was not an efficient use of data in evaluating these associations.
  • CONCLUSION: In this prospective study, we found similar and significantly increased risks of non-cardia and cardia gastric adenocarcinomas in subjects with low PGI/II ratio but little evidence for an association with the risk of OSCC.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Mar10;109(1):138-43 [14735480.001]
  • [Cites] Jpn J Cancer Res. 1995 Jan;86(1):64-71 [7737912.001]
  • [Cites] J Med Screen. 2004;11(3):141-7 [15333273.001]
  • [Cites] Gastroenterology. 1972 Oct;63(4):584-92 [5077145.001]
  • [Cites] Gastroenterology. 1982 Jul;83(1 Pt 2):204-9 [7084603.001]
  • [Cites] Clin Chim Acta. 1987 Mar 16;163(2):191-8 [3568423.001]
  • [Cites] Clin Invest Med. 1987 May;10(3):215-21 [3113799.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):113-7 [8467245.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92 [8360931.001]
  • [Cites] J Clin Gastroenterol. 1993 Jul;17(1):84 [8409305.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):461-6 [8220091.001]
  • [Cites] Ann Epidemiol. 1993 Nov;3(6):577-85 [7921303.001]
  • [Cites] Int J Cancer. 2009 May 1;124(9):2135-8 [19107937.001]
  • [Cites] Dig Dis Sci. 1997 Jul;42(7):1383-7 [9246033.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] World J Gastroenterol. 2005 Feb 21;11(7):1032-6 [15742409.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):463-9 [15688378.001]
  • [Cites] Gut. 2005 Jun;54(6):764-8 [15888780.001]
  • [Cites] J Infect Dis. 2005 Jun 15;191(12):2075-81 [15897993.001]
  • [Cites] Am J Epidemiol. 2006 Apr 1;163(7):629-37 [16443800.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1083-94 [16775164.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):172-6 [17179990.001]
  • [Cites] Gut. 2007 Apr;56(4):457-9 [17369378.001]
  • [Cites] Gut. 2007 Jul;56(7):918-25 [17317788.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):659-72 [17681184.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1603-9 [17488251.001]
  • [Cites] Gut. 2008 Mar;57(3):298-305 [17965056.001]
  • [Cites] Jpn J Clin Oncol. 2008 Apr;38(4):259-67 [18344316.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):874-81 [18484586.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):456-60 [18844222.001]
  • [Cites] BMC Med Res Methodol. 2002;2:4 [11914137.001]
  • [Cites] Gut. 2002 Sep;51(3):457-8 [12171977.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):107-12 [11219766.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • (PMID = 19136509.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] ENG
  • [Grant] United States / CCR NIH HHS / RC / N01-RC-47702; United States / NCI NIH HHS / SC / N01-SC-91030; United States / CCR NIH HHS / RC / N01RC47701; United States / CCR NIH HHS / RC / N01RC47702; United States / Intramural NIH HHS / / ZIA CP000112-05; United States / CCR NIH HHS / RC / N01-RC-47701
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 61536-72-9 / Pepsinogen C; 9001-10-9 / Pepsinogen A
  • [Other-IDs] NLM/ NIHMS159682; NLM/ PMC2792746
  •  go-up   go-down


62. Eskandar H, Hossein SS, Rahim M, Jalal H, Mehrdad A, Rajabi T: Clinical profile of gastric cancer in Khuzestan, southwest of Iran. World J Gastroenterol; 2006 Aug 14;12(30):4832-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical profile of gastric cancer in Khuzestan, southwest of Iran.
  • AIM: To analyze the characteristics of epidemiological, clinical and survival patterns among patients with carcinoma of the stomach.
  • METHODS: We retrospectively studied the characteristics of 186 gastric adenocarcinoma patients at Ahwaz Jundishapur University Hospitals (AJSUH) from September 1, 1996 to September 1, 2002.
  • Demographic variables, family history of gastric cancer (GC), clinicopathologic characteristics and treatment-related variables were analyzed.
  • Adenocarcinoma, gastric lymphoma, and gastric metastasis were found in 94.5%, 2.3%, and 3% patients, respectively.
  • There was an average of 6-mo delay between the initial symptoms and the diagnosis.
  • Among adenocarcinoma groups, intestinal type was the commonest (55.9%) and the distal third was the most common localization (88.4%).
  • Studying the etiology of this cancer in south Iran and earlier diagnosis and subsequent better cares are recommended.
  • [MeSH-major] Stomach Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2000;35 Suppl 12:84-9 [10779225.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):400-5 [11161407.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):811-8 [11857360.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):37-42 [12085253.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):113-8 [12925965.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):37-42 [14693833.001]
  • [Cites] J Chronic Dis. 1971 Nov;24(10):625-33 [4334175.001]
  • [Cites] Surg Gynecol Obstet. 1976 Jul;143(1):113-24 [779084.001]
  • [Cites] Ann R Coll Surg Engl. 1982 Jul;64(4):234-7 [7092091.001]
  • [Cites] Semin Oncol. 1985 Mar;12(1):2-10 [3975643.001]
  • [Cites] Surg Gynecol Obstet. 1992 May;174(5):387-93 [1570616.001]
  • [Cites] Cancer. 1993 May 15;71(10):2926-33 [8490820.001]
  • [Cites] Ann Gastroenterol Hepatol (Paris). 1994 Nov-Dec;30(6):283-6 [7847790.001]
  • [Cites] Ann Ital Chir. 1998 May-Jun;69(3):331-7 [9835105.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Gastrointest Endosc. 1999 Oct;50(4):594-5; discussion 595-6 [10502192.001]
  • [Cites] East Afr Med J. 2000 Jan;77(1):27-30 [10944835.001]
  • (PMID = 16937464.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087616
  •  go-up   go-down


63. Levy MJ, Clain JE, Clayton A, Halling KC, Kipp BR, Rajan E, Roberts LR, Root RM, Sebo TJ, Topazian MD, Wang KK, Wiersema MJ, Gores GJ: Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc; 2007 Sep;66(3):483-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The final diagnosis was based on strict cytopathologic and imaging criteria and 12-month follow-up.
  • PATIENTS: A total of 39 patients were enrolled in whom each diagnostic test was performed on samples from 42 sites to evaluate lymphadenopathy (n=19), pancreatic mass (n=19), esophageal or gastric wall mass (n=3), and thyroid mass (n=1).
  • RESULTS: Malignancy was diagnosed in 30 of 42 patients, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, pancreatic mucinous cystic neoplasia, intraductal papillary mucinous neoplasia, metastatic forearm sarcoma, small cell and non-small cell lung cancer, thyroid carcinoma, malignant GI stromal tumor, melanoma, adenocarcinoma of unknown primary, and lymphoma.
  • [MeSH-major] Biopsy, Fine-Needle. Endosonography. Esophageal Neoplasms / pathology. Image Processing, Computer-Assisted. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Pancreatic Neoplasms / pathology. Stomach Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Esophagus / pathology. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreas / pathology. Pilot Projects. Sensitivity and Specificity. Stomach / pathology


64. Cao G, Ma J, Zhang Y, Liu B, Li F: Pancreatitis-associated protein is related closely to neoplastic proliferative activity in patients with colorectal carcinoma. Anat Rec (Hoboken); 2009 Feb;292(2):249-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatitis-associated protein (PAP) is a secretory protein that is not only expressed during acute pancreatitis but also in pancreatic adenocarcinoma, gastric carcinoma, hepatocellular carcinoma, and colorectal carcinoma.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / genetics. Antigens, Neoplasm / blood. Antigens, Neoplasm / genetics. Biomarkers, Tumor / blood. Biomarkers, Tumor / genetics. Colorectal Neoplasms / blood. Colorectal Neoplasms / genetics. Lectins, C-Type / blood. Lectins, C-Type / genetics

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19051257.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Lectins, C-Type; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / pancreatitis-associated protein
  •  go-up   go-down


65. Lujan M, Cardona AF, Yepes A, Carrasco-Chaumel E, Reveiz L, Otero JM: Myelophthisis in solid tumors: Old aspects, new concepts (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e20672

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven pts (30%) had breast cancer, pathology followed by primary unknown tumours (21%), rabdomiosarcoma (10%), prostate adenocarcinoma (10%), gastric carcinoma (7%) and others (22%).
  • Forty-three pts received chemotherapy following the diagnosis of medullar infiltration, and normal leukocyte count was being seen in 40% of them after such treatment.
  • Nine episodes of febrile neutropenia were found; median overall survival (OS) following the diagnosis of neoplasia and myelophtisis were 13.8 months and 2.2 months respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Li LQ, Wei HJ, Guo ZY, Yang HQ, Xie SS, Chen XM, Li LB, He BH, Wu GY, Lu JJ: [Gastric cancer detection using kubelka-Munk spectral function of DNA and protein absorption bands]. Guang Pu Xue Yu Guang Pu Fen Xi; 2009 Sep;29(9):2499-504
Hazardous Substances Data Bank. BETA-CAROTENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric cancer detection using kubelka-Munk spectral function of DNA and protein absorption bands].
  • Differential diagnosis for epithelial tissues of normal human gastric, undifferentiation gastric adenocarcinoma, gastric squamous cell carcinomas, and poorly differentiated gastric adenocarcinoma were studied using the Kubelka-Munk spectral function of the DNA and protein absorption bands at 260 and 280 nm in vitro.
  • The results of measurement showed that for the spectral range from 250 to 650 nm, pathological changes of gastric epithelial tissues induced that there were significant differences in the averaged value of the Kubelka-Munk function f(r infinity) and logarithmic Kubelka-Munk function log[f(r infinity)] of the DNA absorption bands at 260 nm between epithelial tissues of normal human stomach and human undifferentiation gastric cancer, between epithelial tissues of normal human stomach and human gastric squamous cell carcinomas, and between epithelial tissues of normal human stomach and human poorly differentiated cancer.
  • And pathological changes of gastric epithelial tissues induced that there were significant differences in the averaged value of the Kubelka-Munk function f(r infinity) and logarithmic Kubelka-Munk function log[f(r infinity)] of the protein absorption bands at 280 nm between epithelial tissues of normal human stomach and human undifferentiation gastric cancer, between epithelial tissues of normal human stomach and human gastric squamous cell carcinomas, and between epithelial tissues of normal human stomach and human poorly differentiated cancer.
  • And pathological changes of gastric epithelial tissues induced that there were significant differences in the averaged value of the Kubelka-Munk function f(r infinity) and logarithmic Kubelka-Munk function log[f(r infinity)] of the carotene absorption bands at 480 nm between epithelial tissues of normal human stomach and human undifferentiation gastric cancer, between epithelial tissues of normal human stomach and human gastric squamous cell carcinomas, and between epithelial tissues of normal human stomach and human poorly differentiated cancer.
  • It is obvious that pathological changes of gastric epithelial tissues induced that there were significant changes in the contents of the DNA, protein and beta-carotene of gastric epithelial tissues.
  • The conclusion can be applied to rapid, low-cost and noninvasive the optical biopsy for gastric cancer and provides a useful reference.
  • [MeSH-major] Gastric Mucosa / pathology. Spectrophotometry. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. DNA. Humans. Proteins. beta Carotene

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950661.001).
  • [ISSN] 1000-0593
  • [Journal-full-title] Guang pu xue yu guang pu fen xi = Guang pu
  • [ISO-abbreviation] Guang Pu Xue Yu Guang Pu Fen Xi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteins; 01YAE03M7J / beta Carotene; 9007-49-2 / DNA
  •  go-up   go-down


67. Sym S, Park S, Park J, Kwon K, Jung I, Cho E, Lee W, Chung M, Shin D, Lee J: A randomized phase II trial of weekly docetaxel plus either cisplatin or oxaliplatin in patients with previously untreated advanced gastric cancer: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):4566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of weekly docetaxel plus either cisplatin or oxaliplatin in patients with previously untreated advanced gastric cancer: Preliminary results.
  • METHODS: Chemotherapy-naïve patients with measurable unresectable and/or metastatic gastric adenocarcinoma and a performance status ≤2 were randomly assigned to receive docetaxel (35 mg/m2) weekly on days 1 and 8 of a 21-day cycle plus either cisplatin (60 mg/m2 on day 1) (arm A) or oxaliplatin (120 mg/m2 on day 1) (arm B).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Derici H, Yaman I, Tansug T, Nazli O, Bozdag AD, Isguder AS: Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma. Gastroenterology Res; 2009 Dec;2(6):317-323

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma.
  • BACKGROUND: The purpose of this study is to evaluate perioperative morbidity, mortality and the prognostic factors that influence survival of the patients with transmural advanced gastric carcinoma after curative surgical therapy.
  • METHODS: Fifty patients with transmural advanced gastric adenocarcinoma underwent curative resection in our clinic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990200.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Advanced / Gastric Cancer / Morbidity / Mortality / Survival / Transmural
  •  go-up   go-down


69. Richards DA, Boehm KA, Anthony SP: Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions. Expert Opin Investig Drugs; 2007 Jul;16(7):1059-68
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions.
  • Gastric cancer is a major worldwide problem and is a leading cause of death.
  • The incidence of distal gastric cancer is declining; however, there has been a rapid rise in the incidence of adenocarcinoma of the gastroesophageal junction, which is a more aggressive entity.
  • This review examines recent advances in the treatment of gastroesophageal junction adenocarcinoma and gastric cancer, newer agents and the potential agents that are in development, which can be logically applied to the treatment of this devastating disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drugs, Investigational. Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594189.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Investigational
  • [Number-of-references] 56
  •  go-up   go-down


70. Mróz A, Kiedrowski M, Malinowska M, Sopyło R: Collision tumour of the stomach--adenocarcinoma and neuroendocrine carcinoma: case report and review of the literature. Pol J Pathol; 2009;60(2):94-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumour of the stomach--adenocarcinoma and neuroendocrine carcinoma: case report and review of the literature.
  • We report a rare case of gastric collision tumour composed of poorly differentiated adenocarcinoma and neuroendocrine carcinoma in a 56-year-old Caucasian male.
  • The tumour was located in the gastric body and, to our knowledge, it is the tenth case described in the literature and the first in Poland.
  • The adenocarcinoma component constituted 20% of the lesion and was in a more advanced stage than the neuroendocrine component.
  • Additionally, the adenocarcinoma was the only one to metastasize to regional lymph nodes and the liver.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886184.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


71. Szkaradkiewicz A, Majewski W, Wal M, Czyzak M, Majewski P, Bierła J, Kuch A: Epstein-Barr virus (EBV) infection and p53 protein expression in gastric carcinoma. Virus Res; 2006 Jun;118(1-2):115-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus (EBV) infection and p53 protein expression in gastric carcinoma.
  • In the presented studies p53 protein expression was evaluated in samples of gastric carcinoma originating from 32 selected adult patients (with documented diagnosis of adenocarcinoma of the stomach and without the presence of Helicobacter pylori infection).
  • Among the patients 14 individuals carried EBV-positive gastric carcinoma (group 1) while the 18 remaining patients carried EBV-negative gastric carcinoma (group 2).
  • Presence of p53 protein was noted in 9 (64.3%) cases of EBV-positive gastric cancer (group 1) and in 10 (55.5%) cases of EBV-negative gastric cancer (group 2).
  • The results permit to conclude that abnormalities in p53 in gastric cancer are independent of EBV infection, even if EBV may participate in development of the tumour.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / complications. Stomach Neoplasms / virology. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413625.001).
  • [ISSN] 0168-1702
  • [Journal-full-title] Virus research
  • [ISO-abbreviation] Virus Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


72. Saint-Gerons Marzo S, Catón Santarén B, Anda Fernandez JM: [Metastasis in the palatine tonsil as the first sign of a gastric adenocarcinoma]. Acta Otorrinolaringol Esp; 2005 Nov;56(9):439-40
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastasis in the palatine tonsil as the first sign of a gastric adenocarcinoma].
  • [Transliterated title] Metastasis en la amígdala palatina como primera manifestación de un adenocarcinoma gástrico.
  • Gastric adenocarcinomas rarely give rise to metastases in the palatine tonsils; twelve such cases have been published.
  • We present a patient with a tumour of the palatine tonsil and cervical lymph node involvement who was diagnosed as having an adenocarcinoma of "signet ring" cells in the histopathology and cytology studies.
  • Finding such cells directed us to the stomach in our search for the primary.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Oropharyngeal Neoplasms / secondary. Palatine Tonsil. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353792.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 7
  •  go-up   go-down


73. Schneider S, Krikmann U, Lüüs SM, Kulla A, Haldre S: Neoplastic meningitis as the presenting manifestation of gastric adenocarcinoma. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic meningitis as the presenting manifestation of gastric adenocarcinoma.
  • The aetiology of the chronic meningitis was revealed gastric cancer by gastroscopy, and micrometastasis by bone marrow trephine biopsy.
  • Autopsy confirmed the presence of advanced gastric cancer (adenocarcinoma of signet-ring cell type) with pancreatic involvement, and NM with cancer cells on the meninges, but without infiltration tumour cells into underlying brain parenchyma.
  • We conclude that NM as an initial symptom of gastric cancer is rare and ultimately fatal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] Semin Oncol. 2006 Jun;33(3):312-23 [16769420.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):517-27 [12057097.001]
  • [Cites] Curr Neurol Neurosci Rep. 2002 May;2(3):225-35 [11937001.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):167-74 [15015782.001]
  • [Cites] Lancet Neurol. 2006 May;5(5):443-52 [16632315.001]
  • (PMID = 21785656.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029123
  •  go-up   go-down


74. Rebai W, Fterich F, Makni A, Ksantini R, Bedioui H, Daghfous A, Chebbi F, Jouini M, Ammous A, Kacem M, Ben Safta Z: [Early gastric adenocarcinoma]. Tunis Med; 2010 Jan;88(1):1-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early gastric adenocarcinoma].
  • [Transliterated title] Adénocarcinome superficiel de l'estomac.
  • AIM: the purpose of this study was to determine the epidemiological and clinical behaviour of the superficial adenocarcinoma of the stomach, to clarify its pathological characteristics, its therapy and prognosis.
  • METHODS: Over a period of 14 years (1990-2004), 16 patients were operated for a superficial gastric adenocarcinoma among 155 gastric cancers treated during the same period in the service of general surgery "A" La Rabta.
  • RESULTS: The superficial gastric adenocarcinoma represented 10.3% of our series.
  • Two patients were followed for a chronic stomach ulcer, a patient is followed for Biermer anaemia and another one for Menetrier disease.
  • The cancer was located in the antrum in 8 cases and was multifocal in 3 cases.
  • CONCLUSION: the superficial gastric adenocarcinoma is rare.
  • The follow up of precancerous states allows its diagnosis.
  • The treatment is based on the gastric resection associated to the D1-type lymph node clearance.
  • The multifocal character imposes a surveillance of the remaining gastric stump.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy / methods. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Incidence. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Prognosis. Pyloric Antrum / pathology. Retrospective Studies. Survival Rate. Treatment Outcome. Tunisia / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415204.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


75. Bruna Esteban M, Montalvá Orón E, López Delgado A, Galindo Jara P, Vázquez Prado A, Fabra Ramis R: [Gastric adenocarcinoma in Zinsser-Cole-Engman syndrome]. Cir Esp; 2006 Sep;80(3):176-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma in Zinsser-Cole-Engman syndrome].
  • [Transliterated title] Adenocarcinoma gástrico en el síndrome de Zinsser-Cole-Engman.
  • We report the case of a 37-year-old man with this syndrome who was diagnosed with gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Dyskeratosis Congenita / complications. Stomach Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16956556.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


76. Necula A, Vlad L, Iancu C, Munteanu D, Puia C, Bălă O, AlHajaar N, Pop F, Radu H, Osian G, Graur F, Furcea L, Stanca M, Molnar G, Mocanu L: [Morbidity and mortality in gastric cancer surgery--analysis of 468 cases with gastric adenocarcinoma]. Chirurgia (Bucur); 2008 Sep-Oct;103(5):529-37
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morbidity and mortality in gastric cancer surgery--analysis of 468 cases with gastric adenocarcinoma].
  • [Transliterated title] Morbiditate şi mortalitate în chirurgia cancerului gastric--analiza a 468 cazuri de adenocarcinom gastric.
  • The aim of this study is to evaluate the morbidity and mortality in the surgical treatment of gastric cancer and the factors that could influencing them.
  • We made a retrospective analysis of a group of 468 patients with gastric adenocarcinoma which have been operated in the 3RD Surgical Clinic-Cluj Napoca--01.01.1998-31.12.2003.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Gastrectomy. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260628.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


77. Ilias EJ, Malheiros CA, Kassab P, Castro OA: [Simulation of D1 lymphadenectomy in patients submitted to D2 lymphadenectomy. Prospective study of 57 patients with gastric adenocarcinoma]. Rev Assoc Med Bras (1992); 2006 Jul-Aug;52(4):270-2
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Simulation of D1 lymphadenectomy in patients submitted to D2 lymphadenectomy. Prospective study of 57 patients with gastric adenocarcinoma].
  • [Transliterated title] Linfadenectomia no adenocarcinoma gástrico.
  • BACKGROUND: To simulate a D1 lymphadenectomy in 57 patients who had already been submitted to D2 lymphadenectomy, and analyze stage migration using the Japanese Gastric Cancer Association (JGCA) staging system.
  • CONCLUSION: a) D2 lymphadenectomy is important for the correct staging of gastric cancer;.
  • [MeSH-major] Adenocarcinoma. Gastrectomy. Lymph Node Excision / methods. Stomach Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967148.001).
  • [ISSN] 0104-4230
  • [Journal-full-title] Revista da Associação Médica Brasileira (1992)
  • [ISO-abbreviation] Rev Assoc Med Bras (1992)
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


78. Muñoz Díaz F, García Carrasco C, Monge Romero MI, de Dios Arrebola García J, Soria Monge A: [Acanthosis nigricans as the initial paraneoplastic manifestation of gastric adenocarcinoma]. Gastroenterol Hepatol; 2007 Jan;30(1):15-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acanthosis nigricans as the initial paraneoplastic manifestation of gastric adenocarcinoma].
  • [Transliterated title] Acantosis nigricans como manifestación inicial paraneoplásica de adenocarcinoma gástrico.
  • Initial treatment with topical corticosteroids and oral antihistamines was unsuccessful and, due to suspicion of a paraneoplastic cutaneous syndrome, gastroscopy with sampling for biopsy and abdominal CT were carried out, revealing the existence of an infiltrating gastric adenocarcinoma and underlying adenopathies.
  • [MeSH-major] Acanthosis Nigricans / etiology. Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Paraneoplastic Syndromes / complications. Paraneoplastic Syndromes / diagnosis. Stomach Neoplasms / complications. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17266876.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


79. Muroni M, D'Angelo F, Pezzatini M, Sebastiani S, Noto S, Pilozzi E, Ramacciato G: Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int; 2010 Feb;9(1):97-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma.
  • BACKGROUND: The association between gastric and pancreatic carcinoma is a relatively rare condition.
  • In gastric carcinoma patients, the prevalence of second tumors varies 2.8% to 6.8% according to the reported statistics.
  • Gastric cancer associated with pancreatic cancer is uncommon.
  • Esophagogastroduodenoscopy demonstrated an ulcerative lesion of the gastric antrum.
  • Computed tomography and magnetic resonance showed a gastric thickening in the antral and pyloric portion and a nodular mass (3 X 1.7 cm) in the uncinate portion of the pancreas.
  • Histological examination of the specimen demonstrated a moderately differentiated adenocarcinoma of the stomach and a poorly differentiated ductal adenocarcinoma of the pancreas.
  • CONCLUSIONS: Long survival is rare in patients with associated gastric and pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20133238.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


80. Andreu Garcia M: [Esophageal adenoma-carcinoma and Barrett's esophagus. Gastric adenocarcinoma and Helicobacter pylori]. Gastroenterol Hepatol; 2008 Oct;31 Suppl 4:66-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Esophageal adenoma-carcinoma and Barrett's esophagus. Gastric adenocarcinoma and Helicobacter pylori].
  • [Transliterated title] Adenocarcinoma esfágico y esófago de Barrett. Adenocarcinoma gástrico y Helicobacter pylori.
  • In the last two decades, the incidence of esophageal cancer has progressively increased, especially that of adenocarcinomas localized in the esophagogastric junction.
  • The incidence of gastric cancer has decreased in the last few decades, although this decrease shows wide geographical variations.
  • Thus, the prevalence of gastric cancer continues to be high in countries such as Chile, Colombia and Ireland and this disease remains the most frequent neoplasm in both sexes in China and Japan.
  • In the meeting of the American Gastroenterological Association, notable among all the studies presented on the prevention and treatment of esophageal and gastric cancer were the following contributions: the use of clinical practice guidelines for the prevention and surveillance of Barrett's esophagus (BE) should be improved; treatment with proton pump inhibitors does not seem to reduce the risk of esophageal cancer; endoscopic therapy of intramucosal cancer through complete mucosal resection is effective; Helicobacter pylori eradication prevents the development of metachronous gastric cancer in patients treated for a first intramucosal adenocarcinoma through endoscopic resection; the risk of developing gastric cancer is 6 times higher in patients with mucosa-associated lymphoid tissue (MALT) lymphoma than in the general population; and photodynamic therapy may be an alternative for the treatment of "invisible" gastric adenocarcinoma, which should be followed-up endoscopically.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / etiology. Helicobacter Infections / complications. Helicobacter pylori. Stomach Neoplasms / etiology


81. Kim JY, Park DY, Kim GH, Choi KU, Lee CH, Huh GY, Sol MY, Song GA, Jeon TY, Kim DH, Sim MS: Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma. Histol Histopathol; 2005 04;20(2):543-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma.
  • The purpose of this study was to elucidate Smad4 expression and localization in 65 gastric adenomas, 49 intestinal-type and 39 diffuse type of gastric adenocarcinomas (including 12 cases of fresh frozen tissue) using Real-time RT-PCR and immunohistochemistry.
  • Real-time RT-PCR showed that intestinal type gastric adenocarcinomas have higher Smad4 mRNA expression than diffuse type gastric adenocarcinomas.
  • Immunohistochemical stain for Smad4 revealed that expression of Smad4 was significantly lower in diffuse-type gastric adenocarcinoma than intestinal-type gastric adenocarcinomas.
  • Also, higher Smad4 protein expression in intestinal type gastric adenocarcinomas than overall gastric adenoma was noted.
  • The rate of reduced Smad4 expression was higher in advanced gastric cancer than early gastric cancer.
  • These results suggest that Smad4 might play different roles in human gastric carcinogenesis, especially between intestinal type and diffuse type of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Trans-Activators / genetics. Trans-Activators / metabolism
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Gastric Mucosa / metabolism. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Smad4 Protein. Transforming Growth Factor beta / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15736060.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta
  •  go-up   go-down


82. Necula A, Vlad L, Iancu C, Munteanu D, Puia C, Bălă O, Pop F, Radu H, Al-Hajaar N, Osian G, Graur F, Furcea L, Stanca M, Molnar G, Mocan T: [Clinical aspects with prognostic value in gastric cancer--analysis of 468 cases with gastric adenocarcinoma]. Chirurgia (Bucur); 2008 Mar-Apr;103(2):181-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical aspects with prognostic value in gastric cancer--analysis of 468 cases with gastric adenocarcinoma].
  • [Transliterated title] Aspecte clinice cu implicaţie prognostică în cancerul gastric--analiză a 468 cazuri de adenocarcinom gastric.
  • We made a retrospective analysis of a group of 468 patients with gastric adenocarcinoma which were operated in the 3rd Surgical Clinic--Cluj Napoca--01.01.1998-31.12.2003.
  • The male/female ratio was 1.7:1, this ratio being significantly higher in cases with proximal gastric cancers.
  • This significant group of patients studied has maintained characteristics encountered in populations with higher incidence of gastric adenocarcinoma, men being more frequently affected, distal localization and intestinal histologic type being encountered more frequently.
  • [MeSH-major] Adenocarcinoma / diagnosis. Stomach Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457096.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


83. Riles WL, Erickson J, Nayyar S, Atten MJ, Attar BM, Holian O: Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J Gastroenterol; 2006 Sep 21;12(35):5628-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells.
  • AIM: To investigate the intracellular apoptotic signals engaged by resveratrol in three gastric adenocarcinoma cancer cell lines, two of which (AGS and SNU-1) express p53 and one (KATO-III) with deleted p53.
  • RESULTS: Gastric cancer cells, irrespective of their p53 status, responded to resveratrol with fragmentation of DNA and cleavage of nuclear lamins A and B and PARP.
  • Resveratrol, however, has no effect on mitochondria-associated apoptotic proteins Bcl-2, Bcl-xl, Bax, Bid or Smac/Diablo, and did not promote sub-cellular redistribution of cytochrome C, indicating that resveratrol-induced apoptosis of gastric carcinoma cells does not require breakdown of mitochondrial membrane integrity.
  • CONCLUSION: These findings indicate that even within a specific cancer the intracellular apoptotic signals engaged by resveratrol are cell type dependent and suggest that such differences may be related to differentiation or lack of differentiation of these cells.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Stilbenes / pharmacology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. RESVERATROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2000 Apr;31(4):922-31 [10733549.001]
  • [Cites] Cell Biol Int. 2001;25(4):331-8 [11319839.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1633-9 [11577002.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):991-9 [11581300.001]
  • [Cites] Biochem Pharmacol. 2001 Nov 15;62(10):1423-32 [11709203.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):615-22 [11745454.001]
  • [Cites] N Engl J Med. 2002 Jan 3;346(1):65-7 [11778008.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3247-57 [11714700.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 May;282(5):G809-16 [11960777.001]
  • [Cites] Ann N Y Acad Sci. 2002 May;957:210-29 [12074974.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):91-7 [12085263.001]
  • [Cites] Cancer Lett. 2003 Feb 20;190(2):157-63 [12565170.001]
  • [Cites] BMC Cancer. 2002 Oct 17;2:27 [12383351.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7724-32 [14633697.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):1178-84 [14651997.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):337-46 [14729643.001]
  • [Cites] Mol Cancer Ther. 2004 Jan;3(1):71-84 [14749477.001]
  • [Cites] J Altern Complement Med. 2004 Apr;10(2):235-9 [15165403.001]
  • [Cites] Gastroenterol Jpn. 1987 Aug;22(4):419-27 [2444485.001]
  • [Cites] Science. 1997 Jan 10;275(5297):218-20 [8985016.001]
  • [Cites] Science. 1997 Mar 14;275(5306):1649-52 [9054359.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1808-12 [9581817.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):435-44 [9690535.001]
  • [Cites] Carcinogenesis. 1999 Feb;20(2):237-42 [10069459.001]
  • [Cites] Biochem Pharmacol. 1998 May 1;55(9):1339-46 [10076523.001]
  • [Cites] Drugs Exp Clin Res. 1999;25(2-3):87-97 [10370869.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] World J Gastroenterol. 2005 Jan 14;11(2):280-4 [15633232.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):111-9 [15744586.001]
  • [Cites] Cell Death Differ. 2000 Sep;7(9):834-42 [11042678.001]
  • (PMID = 17007014.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BIRC5 protein, human; 0 / Fas-Associated Death Domain Protein; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Stilbenes; 0 / Tumor Suppressor Protein p53; EC 1.9.3.1 / Electron Transport Complex IV; EC 3.4.22.- / Caspases; Q369O8926L / resveratrol
  • [Other-IDs] NLM/ PMC4088162
  •  go-up   go-down


84. Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Kishino M, Hamab Y, Furukawa S: Diagnostic imaging findings for mandibular metastasis from gastric adenocarcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jun;107(6):e49-53
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic imaging findings for mandibular metastasis from gastric adenocarcinoma.
  • A case of metastatic adenocarcinoma from gastric cancer to the mandibular canine region is reported.
  • [MeSH-major] Adenocarcinoma / secondary. Gingival Neoplasms / secondary. Mandibular Neoplasms / secondary. Osteolysis / radiography. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464643.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Adán-Merino L, Gómez-Senent S, Froilán-Torres C, Suárez J, Martín- Arranz E, Larrauri J, Mora-Sanz P, Segura-Cabral JM, Aldeguer-Martinez M: [Gastric adenocarcinoma in young adults; comparative study with older patients]. Rev Gastroenterol Mex; 2010;75(3):253-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma in young adults; comparative study with older patients].
  • [Transliterated title] Adenocarcinoma gástrico en adultos jóvenes; estudio comparativo con pacientes mayores.
  • BACKGROUND: Gastric adenocarcinoma (GA) has been considered a disease of elderly age and has been rarely reported in patients younger than 35 years of age.
  • The aim of thisΩ demographic, clinicopathological and prognosis of gastric cancer in young patients and to compare their features with the behavior in elder adults.
  • CONCLUSION: Gastric adenocarcinoma is rare in young patients and most cases presented at advanced clinical stage similar to elderly patients, so the prognosis in both age groups is poor.
  • For this reason is important to be aware of alarm symptoms and risk factors in order to perform an early endoscopic diagnosis and a treatment with curative intent.
  • [MeSH-major] Adenocarcinoma / epidemiology. Stomach Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959173.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


86. Chandanos E, Lindblad M, Rubio CA, Jia C, Warner M, Gustafsson JA, Lagergren J: Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer; 2008 May;44(7):1007-14
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure in relation to gastric adenocarcinoma development.
  • Epidemiological research has indicated that the anti-oestrogen tamoxifen, used in breast cancer therapy, may increase the risk of gastric adenocarcinoma of the intestinal but not of the diffuse type.
  • The study participants comprised women in the county of Stockholm who in the Swedish Cancer Register were first recorded with breast cancer and subsequently gastric cancer during the period January 1958-August 2005.
  • Tumour material was reviewed histologically to verify gastric adenocarcinoma diagnosis and classify these cancers into intestinal or diffuse type.
  • Intestinal adenocarcinomas were analysed immunohistochemically for the presence of ER alpha, beta and beta cx.
  • Amongst 68 women with verified gastric adenocarcinoma, 30 had been treated with tamoxifen and 38 not.
  • The intestinal type of gastric adenocarcinoma was not more frequent amongst tamoxifen users (27%) than amongst non-users (34%) (p=0.601).
  • There were no material differences between the tamoxifen groups regarding distribution of any of the three ERs of the intestinal adenocarcinoma specimens.
  • Tamoxifen users had a shorter latency between breast cancer and gastric adenocarcinoma (4 versus 13 years) which was similar in the intestinal and diffuse types.
  • This study does not support the hypothesis that tamoxifen increases the isolated risk of the intestinal type, but it indicates that tamoxifen use might accelerate the tumour progression or increase the overall risk of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cohort Studies. Disease Progression. Female. Gastric Mucosa / metabolism. Humans. Middle Aged. Receptors, Estrogen / metabolism. Risk Factors. Stomach / metabolism. Sweden

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394879.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


87. Ott K, Lordick F: [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. Chirurg; 2009 Nov;80(11):1028-34
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint].
  • The prognosis of locally advanced gastric cancer remains poor.
  • Two randomized studies that have been performed in Europe have shown that peri-operative chemotherapy significantly improves the survival of patients with adenocarcinoma of the stomach and of the gastro-esophageal junction.
  • Neither mortality nor complication rate are increased after neoadjuvant chemotherapy for gastric cancer.
  • Patients with locally advanced gastric cancer should always be referred to experienced high volume centers, where the findings are discussed in a multidisciplinary tumor board.
  • [MeSH-major] Adenocarcinoma / surgery. Esophagogastric Junction. Neoadjuvant Therapy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19756431.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


88. Butte JM, Torres J, Duarte I, Guzmán S, Llanos O: [Gastric adenocarcinoma appearing 32 years after the resection of a gastric lymphoma. Report of one case]. Rev Med Chil; 2008 Oct;136(10):1317-20
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma appearing 32 years after the resection of a gastric lymphoma. Report of one case].
  • [Transliterated title] Adenocarcinoma gástrico treinta y dos años post linfoma gástrico.
  • The association of gastric lymphoma and gastric adenocarcinoma in the same patient is uncommon.
  • Pathology demonstrated a gastric lympho-histiocytic non-Hodgkin's lymphoma.
  • An upper gastrointestinal endoscopy showed an ulcerated and proliferative lesion at the gastric stump.
  • Biopsy demonstrated a gastric adenocarcinoma.
  • Gastric stump resection with lymph node dissection was performed.
  • Pathology of the excised specimen showed a moderately differentiated tubular adenocarcinoma of the gastrojejunal anastomoses which infiltrated up to the subserosa.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphoma, Non-Hodgkin / pathology. Neoplasms, Second Primary / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194630.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


89. Han HS, Lee SY, Lee KY, Hong SN, Kim JH, Sung IK, Park HS, Jin CJ, Min YI: Unclassified mucin phenotype of gastric adenocarcinoma exhibits the highest invasiveness. J Gastroenterol Hepatol; 2009 Apr;24(4):658-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unclassified mucin phenotype of gastric adenocarcinoma exhibits the highest invasiveness.
  • BACKGROUND AND AIM: Gastric cancers present with distinctive carcinogenesis pathways that vary with the mucin phenotypes.
  • We attempted to elucidate the relations between the characteristics of the mucin phenotypes of gastric cancer and the tumor invasiveness.
  • METHODS: Gastric adenocarcinomas that were resected surgically between August 2005 and April 2007 were included in the present study.
  • The gastric cancers were subclassified into gastric and intestinal mucin phenotypes if more than 10% of cancer cells exhibited gastric (MUC5AC and/or MUC6) and intestinal (MUC2 or CD10) markers, respectively.
  • RESULTS: The mucin phenotypes of 123 gastric cancers were gastric (n = 31), intestinal (n = 43), mixed (n = 28) and unclassified (n = 21).
  • The mucin phenotype was related to histological type (P < 0.001), Lauren's classification (P = 0.001) and size (P = 0.014) of the gastric adenocarcinoma, but not to its location or to the presence of Helicobacter pylori infection.
  • CONCLUSION: The mucin phenotype reflects the biological behavior of gastric cancer, with the intestinal and unclassified mucin phenotypes exhibiting the lowest and highest invasiveness, respectively.
  • [MeSH-major] Adenocarcinoma / chemistry. Mucins / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175827.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucin-6; 0 / Mucins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


90. Sánchez-Fayos P, Martín Relloso MJ, González Guirado A, Porres Cubero JC: [Gastric adenocarcinoma: approach to a complex biological reality]. Med Clin (Barc); 2007 Jan 13;128(1):21-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma: approach to a complex biological reality].
  • [Transliterated title] Adenocarcinoma gástrico: intento de aproximación a una realidad biológica compleja.
  • The authors review the complex biological reality of gastric adenocarcinoma from several viewpoints.
  • A good knowledge of this complex biological reality will allow the identification of better markers for an early diagnosis as well as vulnerable etiopathogenetic points for a useful prevention and therapy.
  • [MeSH-major] Adenocarcinoma. Stomach Neoplasms
  • [MeSH-minor] Achlorhydria / complications. Aged. Diet / adverse effects. Early Diagnosis. Epithelial Cells / cytology. Epithelial Cells / pathology. Female. Gastric Mucosa / pathology. Gastritis, Atrophic / complications. Helicobacter Infections / complications. Helicobacter pylori. Humans. Incidence. Male. Metaplasia. Middle Aged. Mitosis. Precancerous Conditions / chemically induced. Precancerous Conditions / pathology. Risk Factors. Stomach / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17266889.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 107
  •  go-up   go-down


91. Kavgaci H, Reis A, Ozdemir F, Bektas O, Arslan M, Aydin F: Carcinoma erysipelatoides resulting from gastric adenocarcinoma: an unusual clinical presentation. Med Princ Pract; 2005 Jan-Feb;14(1):61-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma erysipelatoides resulting from gastric adenocarcinoma: an unusual clinical presentation.
  • OBJECTIVE: To report a rare case of carcinoma erysipelatoides on the laryngeal skin caused by stomach adenocarcinoma.
  • CLINICAL PRESENTATION AND INTERVENTION: A 48-year-old male, who had undergone a gastrectomy 18 months prior to admission for stage IIIA gastric adenocarcinoma, presented with a reddish induration of the cervical skin, lymphadenopathy in both supraclavicular areas and widespread subcutaneous nodules.
  • CONCLUSION: We recommend combination chemotherapy in patients with cutaneous metastasis of gastric adenocarcinoma as a safe and effective treatment.
  • [MeSH-major] Adenocarcinoma / secondary. Head and Neck Neoplasms / secondary. Skin Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15608485.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


92. Lee SH, Choi WC, Kim KS, Park JW, Lee SH, Yoon SW: Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract. J Altern Complement Med; 2010 Apr;16(4):497-500
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract.
  • PATIENT AND METHOD: We present here the case of a female patient (82 years old) with an adenocarcinoma of the stomach that was first diagnosed via an abdomen computed tomography (CT) scan and endoscopic biopsy.
  • CONCLUSIONS: We suggest that RVS extract could be a candidate for a natural agent that induces selective apoptosis and inhibits cell growth in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Flavonoids / therapeutic use. Phytotherapy. Plant Extracts / therapeutic use. Rhus. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423218.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Plant Extracts
  •  go-up   go-down


93. Kim JY, Bae BN, Kim KS, Shin E, Park K: Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. Cancer Res Treat; 2009 Mar;41(1):29-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma.
  • PURPOSE: Osteopontin (OPN) binds to CD44 and nuclear factor-kappaB (NFkappaB) and OPN mediates tumorigenesis, invasion and metastasis, but the interrelationships between OPN, CD44 and NFkappaB are not fully understood, and especially in gastric carcinogenesis.
  • We examined the expressions of OPN, CD44, and NFkappaB in untreated gastric adenocarcinomas.
  • MATERIALS AND METHODS: The materials from 211 cases of gastric adenocarcinoma were immunostained for OPN, CD44 and NFkappaB by using a tissue microarray.
  • RESULTS: The expression of OPN, CD44 and NFkappaB was noted in 61.7%, 11.4% and 26.6% of the adenocarcinoma tissues, respectively.
  • The OPN mRNA expression showed no significant difference between the adenocarcinoma and the paired normal mucosa on real-time RT-PCR.
  • CONCLUSION: OPN may have a currently undetermined role in gastric carcinogenesis, and CD44 and NFkappaB may have minor roles in gastric adenocarcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2009 Jan 30;284(5):2657-71 [19047049.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):44926-35 [11564733.001]
  • [Cites] J Neurooncol. 2008 Feb;86(3):285-96 [17928956.001]
  • [Cites] Gut. 2007 Jun;56(6):782-9 [17148500.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2089-97 [17332338.001]
  • [Cites] Mol Cancer. 2007;6:6 [17227585.001]
  • [Cites] Scand J Surg. 2006;95(4):225-31 [17249269.001]
  • [Cites] J Oral Pathol Med. 2007 Jan;36(1):30-4 [17181739.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Sep;90(9):5270-8 [15998773.001]
  • [Cites] Mol Carcinog. 2005 Aug;43(4):225-36 [15864800.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3526-35 [15908663.001]
  • [Cites] Carcinogenesis. 2005 Apr;26(4):741-51 [15661802.001]
  • [Cites] Clin Exp Metastasis. 2004;21(6):515-23 [15679049.001]
  • [Cites] J Biol Chem. 2005 Jan 28;280(4):2708-13 [15557322.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Mar;12(1):67-70 [15163022.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4541-50 [14623895.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):14487-97 [12473670.001]
  • [Cites] Oncogene. 2003 Feb 27;22(8):1198-205 [12606946.001]
  • [Cites] Genes Dev. 2002 Dec 1;16(23):3074-86 [12464636.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):419-29 [12013531.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Mar;23(3):351-65 [18318820.001]
  • (PMID = 19688069.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2699089
  • [Keywords] NOTNLM ; Adenocarcinoma / CD44 / NFκB / Osteopontin / Stomach
  •  go-up   go-down


94. van Lier MG, Bomhof FJ, Leendertse I, Flens M, Balk AT, Loffeld RJ: Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia. J Clin Pathol; 2005 Jul;58(7):722-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia.
  • BACKGROUND: It is sometimes difficult to distinguish between cardia cancer and oesophageal cancer.
  • METHODS: Consecutive patients with a malignant tumour in the oesophagus or stomach were recruited.
  • RESULTS: Endoscopically located adenocarcinoma of the oesophagus was present in 84 patients (64 men, 20 women; mean age, 68 years; range, 44-91).
  • Cancer located primarily in the gastric cardia was present in 63 patients (42 men, 21 women; mean age, 68 years; range, 42-88).
  • The histological diagnosis was metastasis from a primary tumour outside the oesophagus or stomach in 19 patients.
  • Patients in group A had definite oesophageal cancer, group B patients had a definite carcinoma located in the gastric cardia, and group C patients had an obstructing tumour distal in the oesophagus at the level of the diaphragm, which could not be passed with the endoscope.
  • CONCLUSION: CK phenotyping cannot distinguish between cancer arising from a Barrett's oesophagus and carcinoma originating in the gastric cardia.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cardia. Esophageal Neoplasms / diagnosis. Keratins / metabolism. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Barrett Esophagus / diagnosis. Barrett Esophagus / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):288-94 [10088547.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):445-54 [11962749.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):611-6 [12065774.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1213-21 [12218578.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2514-23 [12385432.001]
  • [Cites] Neth J Med. 2003 Jan;61(1):14-8 [12688564.001]
  • [Cites] Histopathology. 2003 Aug;43(2):127-34 [12877727.001]
  • [Cites] Pathol Res Pract. 2003;199(9):581-7 [14621193.001]
  • [Cites] Histopathology. 2003 Nov;43(5):453-61 [14636271.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):371-6 [15017595.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):487-94 [9309399.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):933 [9314878.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):820-31 [11857318.001]
  • (PMID = 15976339.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC1770716
  •  go-up   go-down


95. Oblak I, Velenik V, Anderluh F, Strojan P: Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia. Eur J Surg Oncol; 2007 Oct;33(8):982-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia.
  • AIMS: To analyze the results of postoperative concomitant radiochemotherapy with 5-florouracil (5-FU) and leucovorin (LV) in patients with gastric carcinoma treated in a single institution.
  • METHODS: During 2001-2004, 123 patients with the mean age of 60 years, were treated for adenocarcinoma of the stomach, stage Ib-IV, with postoperative concomitant radiochemotherapy.
  • In the multivariate analysis, the initial Hb level was identified as independent prognostic factor for all survival four endpoints, the involvement of whole stomach with cancer for LRC, the total dose of 5-FU per five-day cycle for DFS, and pT stage for DSS.
  • CONCLUSIONS: In operable gastric carcinoma, postoperative concomitant radiochemotherapy with 5-FU and LV is feasible and its toxicity acceptable.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258881.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Yu HP, Yu XH, Zhang SX: [Expression and significance of macrophage migration inhibitory factor in gastric adenocarcinoma]. Zhonghua Yi Xue Za Zhi; 2010 Oct 12;90(37):2625-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of macrophage migration inhibitory factor in gastric adenocarcinoma].
  • OBJECTIVE: To investigate the expression of MIF on the gastric adenocarcinoma, evaluate the relation between the MIF expression and tumor differentiation, lymph node metastasis and other clinical patho-features.
  • METHODS: 120 gastric adenocarcinoma cancer tissues, 40 tissues besides cancer and 40 common mucosa tissues specimens are collected.
  • RESULTS: Positive rate of MIF expression in gastric cancer is 80.8% (97/120).
  • Those in poorly differentiated, moderately differentiated and well-differentiated gastric adenocarcinoma are 97.5% (39/40), 82.5% (33/40), 62.5% (25/40), analytical factor of Spearman rank correlation r(s) is 0.458 (χ(2) = 27.046, P < 0.001).
  • Positive rate of MIF expression in tissues besides cancer is 40% (16/40) and that in normal gastric mucosa is 7.5% (3/40).
  • Positive rate of MIF expression in gastric adenocarcinoma without lymph node metastasis is 40% (22/55) and the rate with lymph node metastasis is 67% (44/65).
  • CONCLUSIONS: There is overexpression of MIF in the gastric adenocarcinoma.
  • Expression of MIF in different differentiated cancer is different.
  • Expression in poorly differentiated is higher than that in moderately differentiated and well-differentiated cancer.
  • The level of expression of MIF malignancy has positive correlation with malignancy degree of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Intramolecular Oxidoreductases / metabolism. Macrophage Migration-Inhibitory Factors / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21162929.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Macrophage Migration-Inhibitory Factors; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.2.1 / MIF protein, human
  •  go-up   go-down


97. Sarela AI, Yelluri S, Leeds Upper Gastrointestinal Cancer Multidisciplinary Team: Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg; 2007 Feb;142(2):143-9; discussion 149
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary?
  • HYPOTHESIS: For distant metastatic (M1) gastric adenocarcinoma, a policy to maximally avoid resection of the primary tumor is safe and efficacious.
  • PATIENTS: Sixty-seven (32%) of 211 consecutive patients with adenocarcinoma of the stomach or gastroesophageal junction had synchronous M1 disease on computed tomography or laparoscopy.
  • RESULTS: Fourteen patients (25%) had intervention a median of 5 months after diagnosis.
  • Intervention was for gastric obstruction (20%), bleeding (7%), or perforation (2%).
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309965.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


98. An JY, Kim JY, Choi MG, Noh JH, Choi D, Sohn TS, Kim S: Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma. Yonsei Med J; 2008 Dec 31;49(6):1046-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma.
  • The prognosis for gastric cancer with liver metastasis continues to be poor.
  • We present our preliminary findings from 4 cases of liver metastasis from gastric adenocarcinomas treated using radiofrequency ablation (RFA).
  • Between 1995 and 2004, the clinical history and course of 4 patients who underwent radiofrequency ablation for liver metastases from gastric cancer were reviewed.
  • Although this study was limited to a few cases and had a short follow-up duration, our findings suggest that RFA may provide an alternative treatment modality for liver metastasis resulting from gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Catheter Ablation / methods. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterol Clin Biol. 1999 Nov;23(11):1128-33 [10651531.001]
  • [Cites] Surg Gynecol Obstet. 1989 Oct;169(4):371-85 [2476864.001]
  • [Cites] Surg Today. 2000;30(11):1041-5 [11110405.001]
  • [Cites] Am J Surg. 2001 Mar;181(3):279-83 [11376587.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):86-91 [11753046.001]
  • [Cites] Arch Surg. 2002 Apr;137(4):422-6; discussion 427 [11926946.001]
  • [Cites] Hepatogastroenterology. 2002 Jul-Aug;49(46):1062-5 [12143202.001]
  • [Cites] J Gastrointest Surg. 2002 Sep-Oct;6(5):682-9 [12399057.001]
  • [Cites] Surgery. 2003 May;133(5):507-11 [12773978.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1560-3 [14571786.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):356-9 [6158880.001]
  • [Cites] Hepatogastroenterology. 1997 May-Jun;44(15):897-900 [9222711.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Oct;31(11):1737-9 [15553699.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):459-66 [15886903.001]
  • [Cites] Am Surg. 2005 Feb;71(2):95-9 [16022005.001]
  • [Cites] Ann Ital Chir. 2005 Jan-Feb;76(1):39-41 [16035670.001]
  • [Cites] Semin Radiat Oncol. 2005 Oct;15(4):265-72 [16183480.001]
  • [Cites] J Vasc Interv Radiol. 2005 Dec;16(12):1747-51 [16371545.001]
  • [Cites] World J Gastroenterol. 2005 Oct 28;11(40):6395-401 [16419172.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1619-25 [11090390.001]
  • (PMID = 19108032.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628018
  •  go-up   go-down


99. Chekrine T, Tawfiq N, Bouchbika Z, Benchakroun N, Jouhadi H, Sahraoui S, Benider A: [Ocular metastasis heralding gastric adenocarcinoma]. Rev Med Interne; 2010 Oct;31(10):e14-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ocular metastasis heralding gastric adenocarcinoma].
  • [Transliterated title] Métastase oculaire inaugurale d'un adénocarcinome gastrique.
  • Ocular metastasis is a rare presenting feature of gastric adenocarcinoma.
  • Diagnostic work-up identified a gastric adenocarcinoma with pulmonary metastases.
  • The patient died 6 months after the diagnosis of respiratory failure.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20554090.001).
  • [ISSN] 1768-3122
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


100. Javier M, Loarte A, Pilco P: [Nutritional evaluation in patients with total and partial gastrectomy for gastric adenocarcinoma]. Rev Gastroenterol Peru; 2008 Jul-Sep;28(3):239-43
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nutritional evaluation in patients with total and partial gastrectomy for gastric adenocarcinoma].
  • [Transliterated title] Evaluación nutricional en pacientes con gastrectomía total y parcial por adenocarcinoma gástrico.
  • INTRODUCTION: Gastric adenocarcinoma is still one of the most frequent causes of mortality due to cancer in the world.
  • OBJECTIVE: Evaluate the nutritional state of patients with a total or partial gastrectomy due to gastric adenocarcinoma.
  • PATIENTS AND METHODS: Descriptive study with a transversal cut, which included 14 patients with gastrectomy due to gastric adenocarcinoma, with a minimum evolution time of five months since the gastrectomy was performed.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Nutritional Status. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958139.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down






Advertisement